<SEC-DOCUMENT>0001477932-24-005967.txt : 20240927
<SEC-HEADER>0001477932-24-005967.hdr.sgml : 20240927
<ACCEPTANCE-DATETIME>20240926210823
ACCESSION NUMBER:		0001477932-24-005967
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20240926
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240927
DATE AS OF CHANGE:		20240926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cosmos Health Inc.
		CENTRAL INDEX KEY:			0001474167
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		ORGANIZATION NAME:           	07 Trade & Services
		IRS NUMBER:				270611758
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41308
		FILM NUMBER:		241330300

	BUSINESS ADDRESS:	
		STREET 1:		5 AGIOU GEORGIOU, PILEA
		CITY:			THESSALONIKI
		STATE:			J3
		ZIP:			55438
		BUSINESS PHONE:		312-536-3102

	MAIL ADDRESS:	
		STREET 1:		5 AGIOU GEORGIOU, PILEA
		CITY:			THESSALONIKI
		STATE:			J3
		ZIP:			55438

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cosmos Holdings Inc.
		DATE OF NAME CHANGE:	20140106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRIME ESTATES & DEVELOPMENTS INC
		DATE OF NAME CHANGE:	20091008
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cosm_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cosm="http://cosm.com/20240926"><head><title>cosm_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html"/></head><body style="text-align:justify;font:10pt times new roman"><div style="display:none;text-align:justify;font:10pt times new roman;margin-left:7%;margin-right:7%;" id="XBRLDIV"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2024-09-26to2024-09-26" id="ixv-400">0001474167</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2024-09-26to2024-09-26" format="ixt:booleanfalse" id="ixv-401">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cosm-20240926.xsd"/></ix:references><ix:resources><xbrli:context id="From2024-09-26to2024-09-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001474167</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-26</xbrli:startDate><xbrli:endDate>2024-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:18pt">FORM&#160;<ix:nonNumeric name="dei:DocumentType" contextRef="From2024-09-26to2024-09-26" id="ixv-421">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Date of Report (Date of earliest event reported)&#160;<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="From2024-09-26to2024-09-26" format="ixt:datemonthdayyearen" id="ixv-422">September 26, 2024</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="From2024-09-26to2024-09-26" id="ixv-423">COSMOS HEALTH INC.</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td style="width:39%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:32%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:stateprovnameen" id="ixv-424">Nevada</ix:nonNumeric></strong></p></td><td style="width:2%;"/><td style="BORDER-BOTTOM: 1px solid;width:32%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityFileNumber" contextRef="From2024-09-26to2024-09-26" id="ixv-425">000-54436</ix:nonNumeric></strong></p></td><td style="width:2%;"/><td style="BORDER-BOTTOM: 1px solid;width:32%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="From2024-09-26to2024-09-26" id="ixv-426">27-0611758</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(State or other jurisdiction</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">of incorporation)</p></td><td/><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Commission</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">File Number)</p></td><td/><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(I.R.S. Employer</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Identification No.)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="From2024-09-26to2024-09-26" id="ixv-427">5 AGIOU GEORGIOU</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="From2024-09-26to2024-09-26" id="ixv-428">Pilea</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="From2024-09-26to2024-09-26" id="ixv-429">Thessaloniki</ix:nonNumeric>,&#160;<ix:nonNumeric name="dei:EntityAddressCountry" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:countrynameen" id="ixv-430">Greece</ix:nonNumeric></strong></p></td><td style="width:10%;"/><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="From2024-09-26to2024-09-26" id="ixv-431">55438</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Address of principal executive offices)</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Zip Code)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">Registrant&#8217;s telephone number, including area code&#160;<strong>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="From2024-09-26to2024-09-26" id="ixv-432">312</ix:nonNumeric>)&#160;<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="From2024-09-26to2024-09-26" id="ixv-433">865-0026</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>N/A</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Title of Each Class</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Trading</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Symbol</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:32%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Name of Each Exchange</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>On Which Registered</strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="From2024-09-26to2024-09-26" id="ixv-434">Common Stock, $.001 par value</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="From2024-09-26to2024-09-26" id="ixv-435">COSM</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:exchnameen" id="ixv-436">Nasdaq</ix:nonNumeric>&#160;Capital Market</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:boolballotbox" id="ixv-437">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:boolballotbox" id="ixv-438">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:boolballotbox" id="ixv-439">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:boolballotbox" id="ixv-440">&#9744;</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b of this chapter).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Emerging growth company&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2024-09-26to2024-09-26" format="ixt-sec:boolballotbox" id="ixv-441">&#9744;</ix:nonNumeric></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"/></tr><tr><td style="BORDER-BOTTOM: 5px solid;"/></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"/></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On December 28, 2023, Cosmos Health Inc. (the &#8220;Company&#8221;) entered into a warrant exchange agreement (the &#8220;Warrant Exchange Agreement&#8221;) with one holder (the &#8220;Holder&#8221;) of certain of the Company&#8217;s outstanding warrants issued on July&#160;21, 2023 and December 21, 2022 (the &#8220;Existing Warrants&#8221;), pursuant to which the Holder received new warrants (the &#8220;December 2023 New Warrants&#8221;) to purchase up to an aggregate of 4,874,126 shares of common stock, par value $0.001 per share (the &#8220;New Warrant Shares&#8221;), equal to 200% of the 2,437,063 shares of common stock issuable pursuant to the exercise of the Existing Warrants, in consideration for exercising for cash any and all of such Existing Warrants.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">On September 26, 2024, pursuant to an offer to exercise the existing December 2023 New Warrants from the Company to the Holder (the &#8220;Inducement Offer&#8221;), the Holder and the Company agreed that: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">the Holder will receive new warrants (the &#8220;2024 New Warrants&#8221;) to purchase up an aggregate of 9,748,252 shares (the &#8220;New Warrant Shares&#8221;) of common stock, par value $0.001 per share, equal to 200% of the 4,874,126 New Warrant Shares issued to the Holder on December 28, 2023;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In consideration of the issuance of the 2024 New Warrants, pursuant to the Inducement Offer and the Company&#8217;s agreement that the December 2023 New Warrants, which were issued more than six (6) months ago, may be exercised without receipt of Stockholder Approval (as defined in the December 2023 New Warrants), the Holder will pay to the Company the reduced exercise price of $0.8701 per share;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In consideration for exercising the December 2023 New Warrants, the Company will issue to the Holder: </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(i)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">new unregistered Series A common stock purchase warrants (the &#8220;Series A Warrants&#8221;), to purchase up to a number of shares (the &#8220;Series A Warrant Shares&#8221;) of common stock, equal to 100% of the number of&#160;New Warrant Shares, and</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(ii)</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">new unregistered Series B common stock purchase warrants (the &#8220;Series B Warrants&#8221;) to purchase up to a number of shares of common stock, equal to 100% of the number of New Warrant Shares.</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The Series A Warrants will be exercisable at any time on or after the Stockholder Approval Date (as defined in the 2024 New Warrants), and have a term of exercise of five (5) years from the Stockholder Approval Date. The Series B Warrants will be exercisable at any time on or after the Stockholder Approval Date (as defined in the 2024 New Warrants), and have a term of exercise of eighteen (18) months from the Stockholder Approval Date. The 2024 New Warrants will have an exercise price per share equal to $0.95, a premium to the closing price of $0.8701 of the Company&#8217;s common stock on September 26, 2024.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">In connection with the Inducement Offer, A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) has acted as financial advisor.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The foregoing summaries of the 2024 New Warrants do not purport to be complete and are subject to, and qualified in their entirety by, the Form of&#160;Series A Warrant, the Form of Series B Warrant, and the Form of Inducement Offer Letter, attached as Exhibits 4.1, 4.2 and 10.1, respectively, to this Current Report on Form 8-K, which are incorporated herein by reference.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 33.75pt; text-align:justify;">The information contained above under Item 1.01 of this Current Report on Form 8-K in relation to the 2024 New Warrants is incorporated herein by reference. The issuance of the 2024 New Warrants is being made in reliance upon the exemption from registration provided by Sections 3(a)(9) and 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated thereunder. AGP acted as financial advisor and will be paid 6% of the gross proceeds raised by the Company in this transaction plus legal expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 33.75pt; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>ITEM 9.01&#160;FINANCIAL STATEMENTS AND EXHIBITS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">(d)&#160;Exhibits&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Number</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="width:7%;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cosm_ex41.htm">4.1</a></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cosm_ex41.htm">Form of&#160;Series A Warrant</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cosm_ex42.htm">4.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cosm_ex42.htm">Form of Series B Warrant</a></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cosm_ex101.htm">10.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><a href="cosm_ex101.htm">Form of Inducement Offer Letter</a></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">104</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style="page-break-after: always"></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SIGNATURES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>COSMOS HEALTH INC.</strong></p></td><td/></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Date: September 27, 2024</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">By:</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><em>/s/ Georgios Terzis</em></p></td><td/></tr><tr style="height:15px"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Georgios Terzis</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td/><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Chief Financial Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>cosm_ex41.htm
<DESCRIPTION>FORM OF SERIES A WARRANT
<TEXT>
<html><head><title>cosm_ex41.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.1&nbsp; </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><strong>NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>SERIES A WARRANT</strong><strong> </strong><strong>TO</strong><strong> </strong><strong>PURCHASE SHARES</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>COMMON</strong><strong> </strong><strong>STOCK</strong><strong>&nbsp;</strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong>COSMOS HEALTH INC.</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">Warrant Shares: 4,874,126&nbsp;&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="text-align:right;margin:0px">Issue Date: September 27, 2024</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin:0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p> <p style="margin: 0px"></p> <p style="MARGIN: 0px 0px 0px 5.5pt; TEXT-INDENT: 27.1pt; text-align:justify;">THIS SERIES A<strong> </strong>WARRANT TO PURCHASE SHARES OF COMMON STOCK (this &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the &#8220;<u>Initial</u><u> Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on the five (5) year anniversary of the Stockholder Approval Date (as defined below) but not thereafter (the &#8220;<u>Termination Date</u>&#8221;, to subscribe for and purchase from COSMOS HEALTH INC., a corporation incorporated under the laws of the State of Nevada (the &#8220;<u>Company</u>&#8221;), up to 4,874,126 shares of Common Stock, par value $0.001 per share (the &#8220;<u>Common Shares</u>&#8221;), of the Company (as subject to adjustment hereunder, the &#8220;<u>Warrant</u> <u>Shares</u>&#8221;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 5.5pt; TEXT-INDENT: 27pt; text-align:justify;"><u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Offer Letter (the &#8220;<u>Offer Letter</u>&#8221;), dated September 26, 2024, among the Company and the holder signatory thereto. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof. The Company shall use its reasonable best efforts to obtain all components of the Stockholder Approval. If the Company does not obtain all components of the Stockholder Approval at Meetings prior to the seventieth (70<sup style="vertical-align:super">th</sup>) day following the Closing Date, the Company shall call additional Meetings every sixty (60) days thereafter to seek any remaining components of the Stockholder Approval. If the Company does not obtain all components of the Stockholder Approval at such additional Meetings, the Company shall call a Meeting every seventy (70) days thereafter to seek any remaining components of the Stockholder Approval using printed proxy materials until the date that all components of the Stockholder Approval are obtained. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Stockholder Approval Date</u>&#8221; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for trading for a period of time less than the customary time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Globex Transfer, LLC, the current transfer agent of the Company, with a mailing address of 780 Deltona Boulevard, Suite 202, Deltona, FL&nbsp; 32725, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 1. <u>Definitions</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 2. <u>Exercise</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrants available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) <u>Exercise Price</u>. The exercise price under this Warrant shall be $0.95 per share, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Cashless Exercise</u>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrants to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:justify;">(A) = as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;at the option of the Holder, either (x)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y)&nbsp;the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;Bloomberg&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:justify;">(B) = the Exercise Price, as adjusted hereunder; and</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Mechanics of Exercise</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of the Warrant Shares, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Shares Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, at the option of the Holder either (A) in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until the earlier of such Warrant Shares being delivered or Holder rescinds such exercise or (B) the amount pursuant to a Buy-In pursuant to Section 2(d)(iv) hereof. The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Offer Letter, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">vi. <u>Charges, Taxes and Expenses</u>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates, and (iii) any other Persons whose beneficial ownership of the shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock underlying the Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of the Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 3. <u>Certain Adjustments</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Share Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse share split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares 7of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) [RESERVED]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&#8217;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or more than 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&nbsp; For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&nbsp; If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&nbsp; Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder, as described below, an amount of consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction, provided, however, that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction the same type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.&nbsp; &#8220;Black Scholes Value&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;Bloomberg&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the greater of (i)&nbsp;the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii)&nbsp;the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d), (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section&nbsp;3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">f) [RESERVED]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">g) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">h) <u>Notice to Holder</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a special nonrecurring cash dividend on or a redemption of the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company is required in connection with a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">iii. <u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 4. <u>Transfer of Warrant</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of the Offer Letter, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of the Offer Letter.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">e) <u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 5. <u>Miscellaneous</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Currency</u>. All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published on Bloomberg on the relevant date of calculation.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">e) <u>Authorized Shares</u>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued, and Warrant Shares, delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant, which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">f) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Offer Letter.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">g) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">h) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Offer Letter, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">i) <u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Offer Letter.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">j) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any share of Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">k) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">l) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">m) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">n) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">o) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">******************</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(<em>Signature Page Follows</em>)</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="margin:0px">COSMOS HEALTH INC.</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:10%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Name:&nbsp; </p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Grigorios Siokas</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Title:&nbsp;&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Chief Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT A</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong>NOTICE OF EXERCISE</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">TO: COSMOS HEALTH INC.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">__________________________________________________</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">__________________________________________________</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:77%;vertical-align:top;"> <p style="text-align:justify;margin:0px">__________________________________________________</p> <p style="text-align:justify;margin:0px">[SIGNATURE OF HOLDER]</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:justify;margin:0px">Name of Investing Entity:<u> </u>_____________________________</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:left;margin:0px">Signature of Authorized Signatory of Investing Entity: </p> <p style="text-align:left;margin:0px">__________________________________________________</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:left;margin:0px">Name of Authorized Signatory: <u>&nbsp;</u></p> <p style="text-align:left;margin:0px">__________________________________________________ </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:left;margin:0px">Title of Authorized Signatory: _________________________</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:justify;margin:0px">Date: _____________________________________________</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><strong>EXHIBIT B</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong>ASSIGNMENT FORM</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</em></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Name:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:38%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">(Please Print)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Address:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:38%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">(Please Print)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Phone Number:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Email Address:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Dated:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Holder&#8217;s Signature:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Holder&#8217;s Address:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>cosm_ex42.htm
<DESCRIPTION>FORM OF SERIES B WARRANT
<TEXT>
<html><head><title>cosm_ex42.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 4.2&nbsp; </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><strong>NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><strong><strong> <p style="MARGIN: 0px; text-align:center;">SERIES B WARRANT TO PURCHASE SHARES OF COMMON STOCK </p></strong></strong> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong>COSMOS HEALTH INC.</strong></strong></p> <p style="margin:0px"> <p style="margin:0px">&nbsp; </p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">Warrant Shares: 4,874,126&nbsp;&nbsp; </p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="text-align:right;margin:0px">Issue Date: September 27, 2024</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">&nbsp;</p> <p style="margin:0px 0px 0px 5.5pt;text-indent:27pt">THIS SERIES B<strong> </strong>WARRANT TO PURCHASE SHARES OF COMMON STOCK (this &#8220;<u>Warrant</u>&#8221;) certifies that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the &#8220;<u>Holder</u>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the &#8220;<u>Initial</u><u> Exercise Date</u>&#8221;) and on or prior to 5:00 p.m. (New York City time) on the eighteen (18) month anniversary of the Stockholder Approval Date (as defined below) but not thereafter (the &#8220;<u>Termination Date</u>&#8221;, to subscribe for and purchase from COSMOS HEALTH INC., a corporation incorporated under the laws of the State of Nevada (the &#8220;<u>Company</u>&#8221;), up to 4,874,126 shares of Common Stock, par value $0.001 per share (the &#8220;<u>Common Shares</u>&#8221;), of the Company (as subject to adjustment hereunder, the &#8220;<u>Warrant Shares</u>&#8221;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</p> <p style="margin:0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 5.5pt; TEXT-INDENT: 27pt; text-align:justify;"><u>Definitions</u>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Offer Letter (the &#8220;<u>Offer Letter</u>&#8221;), dated September 26, 2024, among the Company and the holder signatory thereto. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Affiliate</u>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Bid Price</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the VWAP of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Board of Directors</u>&#8221; means the board of directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Business Day</u>&#8221; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed;&nbsp;<u>provided</u>,&nbsp;<u>however</u>, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Commission</u>&#8221; means the United States Securities and Exchange Commission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Common Stock Equivalents</u>&#8221; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Rule 144</u>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Stockholder Approval</u>&#8221; means such approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the exercise thereof. The Company shall use its reasonable best efforts to obtain all components of the Stockholder Approval. If the Company does not obtain all components of the Stockholder Approval at Meetings prior to the seventieth (70<sup style="vertical-align:super">th</sup>) day following the Closing Date, the Company shall call additional Meetings every sixty (60) days thereafter to seek any remaining components of the Stockholder Approval. If the Company does not obtain all components of the Stockholder Approval at such additional Meetings, the Company shall call a Meeting every seventy (70) days thereafter to seek any remaining components of the Stockholder Approval using printed proxy materials until the date that all components of the Stockholder Approval are obtained. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Stockholder Approval Date</u>&#8221; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Subsidiary</u>&#8221; means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Day</u>&#8221; means any day on which the Trading Market is open for trading, including any day on which the Trading Market is open for trading for a period of time less than the customary time.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Trading Market</u>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>Transfer Agent</u>&#8221; means Globex Transfer, LLC, the current transfer agent of the Company, with a mailing address of 780 Deltona Boulevard, Suite 202, Deltona, FL&nbsp; 32725, and any successor transfer agent of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&#8220;<u>VWAP</u>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 1. <u>Definitions</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 2. <u>Exercise</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Exercise of Warrant</u>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<u>Notice of Exercise</u>&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrants available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">For the avoidance of doubt, there is no circumstance that would require the Company to net cash settle the Warrants.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) <u>Exercise Price</u>. The exercise price under this Warrant shall be $0.95 per share, subject to adjustment hereunder (the &#8220;<u>Exercise Price</u>&#8221;).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Cashless Exercise</u>. Notwithstanding anything to the contrary set forth herein, if at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrants to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:justify;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;Bloomberg&#8221;) as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:justify;">(B) = the Exercise Price, as adjusted hereunder; and</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 63pt; text-align:justify;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Mechanics of Exercise</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">i. <u>Delivery of Warrant Shares Upon Exercise</u>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<u>DWAC</u>&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of the Warrant Shares, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<u>Warrant Shares Delivery Date</u>&#8221;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, at the option of the Holder either (A) in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until the earlier of such Warrant Shares being delivered or Holder rescinds such exercise or (B) the amount pursuant to a Buy-In pursuant to Section 2(d)(iv) hereof. The Company agrees to maintain a registrar (which may be the Transfer Agent) that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#8220;<u>Standard Settlement Period</u>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Offer Letter, the Company agrees to deliver, or cause to be delivered, the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">ii. <u>Delivery of New Warrants Upon Exercise</u>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">iii. <u>Rescission Rights</u>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">iv. <u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#8220;<u>Buy-In</u>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for the Warrant Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrants with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common stock upon exercise of the Warrant as required pursuant to the terms hereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">v. <u>No Fractional Shares or Scrip</u>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">vi. <u>Charges, Taxes and Expenses</u>. The issuance and delivery of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <u>provided</u>, <u>however</u>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">vii. <u>Closing of Books</u>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">e) <u>Holder&#8217;s Exercise Limitations</u>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&#8217;s Affiliates, (ii) any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates, and (iii) any other Persons whose beneficial ownership of the shares of Common Stock would or could be aggregated with the Holder&#8217;s for the purposes of Section 13(d) (such Persons, &#8220;<u>Attribution Parties</u>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock underlying the Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of the Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;), as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#8220;<u>Beneficial Ownership Limitation</u>&#8221; shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. If the Warrant is unexercisable as a result of the Holder&#8217;s Beneficial Ownership Limitation, no alternate consideration is owing to the Holder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 3. <u>Certain Adjustments</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Share Dividends and Splits</u>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse share split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares 7of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant remains unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) [RESERVED]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Subsequent Rights Offerings</u>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Pro Rata Distributions</u>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<u>Distribution</u>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<u>provided</u>, <u>however</u>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Fundamental Transaction</u>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the Company&#8217;s assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding shares of Common Stock or more than 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<u>Fundamental Transaction</u>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<u>Alternate Consideration</u>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder, as described below, an amount of consideration equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction, provided, however, that, if the Fundamental Transaction is not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor Entity, as of the date of the consummation of such Fundamental Transaction the same type or form of consideration (and in the same proportion), valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received shares of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;Black Scholes Value&#8221; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;Bloomberg&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d), (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds within five Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<u>Successor Entity</u>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">f) [RESERVED]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">g) <u>Calculations</u>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share of Common Stock, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">h) <u>Notice to Holder</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">i. <u>Adjustment to Exercise Price</u>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">ii. <u>Notice to Allow Exercise by Holder</u>. If (A) the Company declares a dividend (or any other distribution in whatever form) on the shares of Common Stock, (B) the Company declares a special nonrecurring cash dividend on or a redemption of the shares of Common Stock, (C) the Company authorizes the granting to all holders of the shares of Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company is required in connection with a Fundamental Transaction, or (E) the Company authorizes the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the shares of Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the shares of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">iii. <u>Voluntary Adjustment By Company</u>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 1in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 4. <u>Transfer of Warrant</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Transferability</u>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of the Offer Letter, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) <u>New Warrants</u>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Warrant Register</u>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<u>Warrant Register</u>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Transfer Restrictions</u>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of the Offer Letter.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">e) <u>Representation by the Holder</u>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in;text-indent:0.5in">Section 5. <u>Miscellaneous</u>.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">a) <u>Currency</u>. All dollar amounts referred to in this Warrant are in United States Dollars (&#8220;<u>U.S. Dollars</u>&#8221;). All amounts owing under this Warrant shall be paid in U.S. Dollars. All amounts denominated in other currencies shall be converted in the U.S. Dollar equivalent amount in accordance with the Exchange Rate on the date of calculation. &#8220;<u>Exchange Rate</u>&#8221; means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Warrant, the U.S. Dollar exchange rate as published on Bloomberg on the relevant date of calculation.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">b) <u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">c) <u>Loss, Theft, Destruction or Mutilation of Warrant</u>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate<strong>.</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&nbsp;</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">d) <u>Saturdays, Sundays, Holidays, etc</u>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">e) <u>Authorized Shares</u>. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued shares of Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares underlying this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued, and Warrant Shares, delivered, as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares underlying this Warrant, which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any shares of Common Stock above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.5in; text-align:justify;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">f) <u>Jurisdiction</u>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Offer Letter.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">g) <u>Restrictions</u>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and if the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state, federal or foreign securities laws.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">h) <u>Nonwaiver and Expenses</u>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Offer Letter, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">i) <u>Notices</u>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Offer Letter.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">j) <u>Limitation of Liability</u>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any share of Common Stock or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">k) <u>Remedies</u>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">l) <u>Successors and Assigns</u>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">m) <u>Amendment</u>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">n) <u>Severability</u>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0.5in;text-indent:0.5in">o) <u>Headings</u>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">******************</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;">(<em>Signature Page Follows</em>)</p> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td colspan="2" style="vertical-align:bottom;"> <p style="font-size:10pt;font-family:times new roman;text-align:left;margin:0px">COSMOS HEALTH INC.</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:10%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Name:&nbsp; </p></td> <td> <p style="margin:0px">Grigorios Siokas</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Title:&nbsp;&nbsp;&nbsp;</p></td> <td> <p style="margin:0px">Chief Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT A</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong>NOTICE OF EXERCISE</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">TO: COSMOS HEALTH INC.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(2) Payment shall take the form of (check applicable box):</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; text-align:justify;">&#9744; in lawful money of the United States; or</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1in; text-align:justify;">&#9744; if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">__________________________________________________</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">The Warrant Shares shall be delivered to the following DWAC Account Number:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">__________________________________________________</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:77%;vertical-align:top;"> <p style="text-align:justify;margin:0px">__________________________________________________</p> <p style="text-align:justify;margin:0px">[SIGNATURE OF HOLDER]</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:justify;margin:0px">Name of Investing Entity: _____________________________</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:left;margin:0px">Signature of Authorized Signatory of Investing Entity: </p> <p style="text-align:left;margin:0px">__________________________________________________</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:left;margin:0px">Name of Authorized Signatory: <u>&nbsp;</u></p> <p style="text-align:left;margin:0px">__________________________________________________ </p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:left;margin:0px">Title of Authorized Signatory: _________________________</p></td></tr> <tr style="height:15px"> <td style="width:75%;vertical-align:top;"> <p style="text-align:justify;margin:0px">Date: _____________________________________________</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong><strong>EXHIBIT B</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><strong>ASSIGNMENT FORM</strong></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</em></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Name:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:38%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">(Please Print)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Address:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td style="width:38%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">(Please Print)</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Phone Number:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Email Address:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Dated:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Holder&#8217;s Signature:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:18%;vertical-align:bottom;"> <p style="text-align:justify;margin:0px">Holder&#8217;s Address:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:38%;"> <p style="text-align:justify;margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px"> <p style="margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>cosm_ex101.htm
<DESCRIPTION>FORM OF INDUCEMENT OFFER LETTER
<TEXT>
<html><head><title>cosm_ex101.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT&nbsp;10.1 </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>COSMOS HEALTH INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2 Agiou Georgiou</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Pilea, Thessaloniki</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Greece 55438</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">September 26, 2024</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To the Holder of Warrants to Purchase Shares of Common Stock of Cosmos Health Inc. Issued on December 28, 2023</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="text-align:justify;margin:0px">Re:</p></td> <td style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><u>Inducement Offer to Exercise Existing Common Stock Purchase Warrants</u></p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dear Holder:</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">COSMOS HEALTH INC. (the &#8220;<u>Company</u>&#8221;) is pleased to offer (this &#8220;<u>Inducement Offer</u>&#8221;) to you (&#8220;<u>Holder</u>&#8221;, &#8220;<u>you</u>&#8221; or similar terminology) the opportunity to receive new warrants (the &#8220;<u>New Warrants</u>&#8221;) to purchase up an aggregate of 9,748,252 shares (the &#8220;<u>New Warrant Shares</u>&#8221;) of Common Stock, par value $0.001 per share (the &#8220;<u>Common Stock</u>&#8221;), equal to 200% of the 4,874,126 Warrant Shares issued to you on December 28, 2023 (the &#8220;<u>Existing Warrants</u>&#8221;), as more particularly set forth on the signature page hereto, in consideration for exercising for cash any or all of such Existing Warrants.&nbsp; The issuance, or resale, of shares of Common Stock underlying the Existing Warrants have been registered pursuant to an effective registration statement (File No. 333-276755). The shares of Common Stock underlying the Existing Warrants are referred to herein as the &#8220;<u>Warrant Shares</u>&#8221; and the registration statement referenced in the foregoing sentence is referred to herein as the &#8220;<u>Registration Statement</u>.&#8221; The Registration Statement is currently effective and, upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance or resale of the Warrant Shares, as applicable. Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants (as defined hereinafter).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company is making you this offer during the period from the date of this Offer set forth above and until 7:30 am, Eastern Time, on&nbsp; September 27, 2024&nbsp;(the &#8220;<u>Exercise Period</u>&#8221;). Exercise of the Existing Warrants may be made, in whole or in part, at any time or times during the Exercise Period by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise attached to the Existing Warrants, as applicable; provided, that the exercise of Existing Warrants will be accompanied by payment in full of the Reduced Exercise Price to the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company desires to reduce the Exercise Price of the Existing Warrants to $0.8701 per share (the &#8220;<u>Reduced Exercise Price</u>&#8221;). In consideration for exercising Existing Warrants held by Holder, which the Company agrees may be exercised without receipt of Stockholder Approval (as defined in the Existing Warrants) and each time that the Holder exercises Existing Warrants pursuant to the terms of this Offer (the &#8220;<u>Warrant Exercise</u>&#8221;), the Company hereby offers to issue you or your designees:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; TEXT-INDENT: 0.5in; text-align:justify;">(a)&nbsp;for exercising Existing Warrants, (i) new unregistered Common Stock Series A purchase warrants (collectively, the &#8220;<u>Series A Warrants</u>&#8221;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the &#8220;<u>Securities Act</u>&#8221;), to purchase up to a number of shares (the &#8220;<u>Series A Warrant Shares</u>&#8221;) of Common Stock equal to 100% of the number of Warrant Shares issued pursuant to such exercise of Existing Warrants and (ii) new unregistered Common Stock Series B purchase warrants (collectively, the &#8220;<u>Series B Warrants</u>,&#8221; and together with the Series A Warrants, the &#8220;<u>New Warrants</u>&#8221;) pursuant to Section 4(a)(2) of the Securities Act, to purchase up to a number of shares (the &#8220;<u>Series B Warrant Shares</u>,&#8221; and together with the Series A Warrant Shares, the &#8220;<u>New Warrant Shares</u>&#8221;) of Common Stock equal to 100% of the number of Warrant Shares issued pursuant to such exercise of Existing Warrants, which New Warrants shall be substantially in the forms as set forth in <strong><u>Exhibit B-1</u></strong> and <strong><u>Exhibit B-2</u></strong> hereto.&nbsp; The Series A Warrants will be exercisable at any time on or after the Stockholder Approval Date (as defined in the New Warrants), and have a term of exercise of five (5) years from the Stockholder Approval Date, and the Series B Warrants will be exercisable at any time on or after the Stockholder Approval Date (as defined in the New Warrants), and have a term of exercise of eighteen (18) months from the Stockholder Approval Date.&nbsp; The New Warrants will have an exercise price per share equal to $0.95.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">1</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">(b) New Warrant certificates will be delivered within two (2) Trading Days following the Warrant Exercise, and such New Warrants, together with any underlying shares of Common Stock issuable upon exercise of the New Warrants, shall be registered under the Securities Act pursuant to a Resale Registration Statement (as defined in <u>Annex A</u> hereto) to be filed by the Company in accordance with <u>Annex A</u> hereto. Notwithstanding anything herein to the contrary, in the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&#8220;<u>Beneficial Ownership Limitation</u>&#8221;) set forth in <u>Section 2(e)</u> of the Existing Warrants (or, if applicable and at the Holder&#8217;s election, 9.99%), the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant to a Notice of Exercise in the Existing Warrants (provided no additional exercise price shall be due and payable). The parties hereby agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants is as set forth on the Holder&#8217;s signature page hereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">Expressly subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter below, which constitutes the Holder&#8217;s acceptance to exercise the Existing Warrants at the Holder&#8217;s own discretion subject to the Beneficial Ownership Limitation set forth in <u>Section 2(e)</u> of the Existing Warrants.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Company agrees to the representations, warranties and covenants set forth on <strong><u>Annex A</u></strong> attached hereto. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Holder represents and warrants that, as of the date hereof, the Holder is fully aware of, and has reviewed all of the Company&#8217;s public filings on EDGAR since January 1, 2022, and as of the date hereof the Holder is, and on each date on which it exercises any New Warrants it will be, an &#8220;accredited investor&#8221; as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will not contain restrictive legends when issued, and the New Warrants and the shares of Common Stock issuable upon exercise of the New Warrants will be registered under the Securities Act pursuant to the Resale Registration Statement or a subsequent filing or filings with the U.S. Securities and Exchange Commission (the &#8220;<u>Commission</u>&#8221;). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">The Holder understands that the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act, or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear an appropriate restrictive legend regarding the foregoing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 35.95pt; text-align:justify;">Upon the Holder&#8217;s exercise of the New Warrants, certificates evidencing the New Warrant Shares shall not contain any legend, (i) while a registration statement covering the resale of such New Warrant Shares is effective under the Securities Act, and if necessary, a prospectus supplement, including the Prospectus Supplement, has been filed with the Commission and no stop order preventing or suspending the effectiveness of such registration statement or suspending or preventing the use of such prospectus supplement has been issued by the Commission, (ii) following any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the New Warrants), without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, (iv)&nbsp;if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then in compliance with the current public information requirement under Rule 144 as to such New Warrant Shares, or (v) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission and the earliest of clauses (i) through (v), (the &#8220;<u>Delegend Date</u>&#8221;)). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Delegend Date if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request of the Holder, which opinion shall be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date, such New Warrant Shares shall be issued free of all legends, provided that, upon request of the Company (which request shall also include a form of customary representation letter), the Holder has delivered in advance to the Company a customary representation letter that is reasonably satisfactory to the Company and its counsel. The Company agrees that following the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than two (2) Trading Days following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued with a restrictive legend (such second (2<sup style="vertical-align:super">nd</sup>) Trading Day, the &#8220;<u>Legend Removal Date</u>&#8221;), deliver or cause to be delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request of the Holder, shall credit the account of the Holder&#8217;s prime broker with the Depository Trust Company System as directed by the Holder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 35.95pt; text-align:justify;">In addition to the Holder&#8217;s other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares are submitted to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate representing the New Warrant Shares&nbsp; free from all restrictive and other legends and (b) if after the Legend Removal Date the Holder purchases (in an open market transaction or otherwise) shares of&nbsp;Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of the Holder&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<u>Buy-In Price</u>&#8221;) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by the Legend Removal Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B)&nbsp;the weighted average price at which the Holder sold that number of shares of&nbsp; Common Stock.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 35.95pt; text-align:justify;">If this offer is accepted and the transaction documents are executed on or before&nbsp;11:00 p.m., Eastern Time, on September 26, 2024, then on or before 8:00 a.m., Eastern Time, on the Trading Day following the date hereof, the Company shall file a Current Report on Form 8-K with the Commission disclosing all material terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto with the Commission within the time required by the Exchange Act. From and after the issuance of the filing of such Current Report on Form 8-K, the Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition, effective upon the filing of such Current Report on Form 8-K, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents, warrants and covenants that, upon acceptance of this offer, and upon issuance of the Warrant Shares, the Warrant Shares shall be issued free of any legends or restrictions on resale by Holder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">No later than the first (1<sup style="vertical-align:super">st</sup>) Trading Day following the first Trading Day after the date hereof, the closing (&#8220;<u>Closing</u>&#8221;) shall occur remotely via the exchange of documents and signatures or such other location as the parties shall mutually agree. Prior to the Closing, the Company and the Holder shall enter into an escrow agreement with an escrow agent, mutually agreed upon by the parties (the &#8220;Escrow Agent&#8221;), pursuant to which payment for the Warrant Shares shall be paid by the Holder to the Escrow Agent.&nbsp; Unless otherwise directed by A.G.P./Alliance Global Partners (the &#8220;<u>Financial Advisor</u>&#8221;), settlement of the Warrant Shares shall occur via &#8220;Delivery Versus Payment&#8221; (&#8220;<u>DVP</u>&#8221;) (i.e., on the Closing Date, the Company shall issue the Warrant Shares registered in the Holder&#8217;s name and address provided to the Company in writing and released by the Transfer Agent directly to the account(s) at the Financial Advisor identified by the Holder; upon receipt of such Warrant Shares, the Financial Advisor shall promptly electronically deliver such Warrant Shares to the Holder, and payment therefor shall concurrently be made to the Company by the Escrow Agent by wire transfer to the Company less the compensation, fees and expenses payable to the Financial Advisor and the fees and expenses of the Escrow Agent, which shall be paid by the Company). The date of the Closing of the exercise of the Existing Warrants shall be referred to as the &#8220;<u>Closing Date</u>.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[<em>Signature Page Follows</em>]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="text-align:justify;margin:0px">Sincerely yours,</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:5%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="text-align:justify;margin:0px"><strong>COSMOS HEALTH INC.</strong></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Name: </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Greg Siokas</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Title: </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Chief Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[Cosmos Health Inc. Signature Page to Offer Letter, dated September 26, 2024] </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[Holder Signature Page Follows]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>HOLDER SIGNATURE PAGE TO COSMOS HEALTH INC. AGREEMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accepted and Agreed to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Holder: <u>___________________________________</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Signature of Authorized Signatory of Holder</em>: <u>_________________________________________________</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Name of Authorized Signatory: <strong><u>_____________________________________________________</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Title of Authorized Signatory: <strong><u>______________________________________________________</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Number of Existing Warrants: <strong><u>______________________________________________________ </u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Aggregate Warrant Exercise Price being exercised contemporaneously with signing this letter agreement: <strong><u>$_______________________________________ </u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Existing Warrants Beneficial Ownership Blocker:&nbsp; &#9746; &nbsp;4.99% or&nbsp; &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">New Warrants: (up to 200% of total Existing Warrants): <strong><u>_________________________________</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New Warrants Beneficial Ownership Blocker: &#9746; 4.99% or &#9744; 9.99%</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">DTC Instructions: <strong><u>________________________________________________________________</u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">[Holder signature page to Cosmos Health Inc. Offer Letter]</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>Annex A</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;"><u>Representations, Warranties and Covenants of the Company</u>. The Company hereby makes the following representations, warranties and covenants to the Holder:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">a) <u>SEC Reports</u>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein &#8220;<u>SEC Reports</u>&#8221;). As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading except as otherwise noted in a subsequent SEC Report. The Company has never been an issuer subject to Rule&nbsp;144(i) under the Securities Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">b) <u>Authorization; Enforcement</u>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith, if applicable. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. The New Warrants and New Warrant Shares are duly authorized and the New Warrant Shares, when issued and paid for in accordance with the terms of this letter and the New Warrants , will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Company.&nbsp; The New Warrants constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">c) <u>No Conflicts</u>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&#8217;s certificate or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this letter agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">d) <u>Registration Obligations</u>. On or before the thirty (30) day anniversary of the Closing Date, the Company shall file with the Commission a registration statement on Form S-3 (or other appropriate form if the Company is not then Form S-3 eligible) providing for the resale of the New Warrant Shares by the holders of the New Warrants (the &#8220;<u>Resale Registration Statement</u>&#8221;). The Company shall use commercially reasonable efforts to cause the Resale Registration Statement to become effective within sixty (60) calendar days following the date of filing with the Commission and to keep the Resale Registration Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">e) <u>Trading Market</u>. The transactions contemplated under this letter agreement comply with all the rules and regulations of the Nasdaq Capital Market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">f) <u>Filings, Consents and Approvals</u>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i)&nbsp;the filings required pursuant to this letter agreement; and (ii)&nbsp;application(s) or notice to each applicable Trading Market for the listing of the New Warrants and New Warrant Shares for trading thereon in the time and manner required thereby.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">g) <u>Listing of Common Stock</u>. The Holder is fully aware of, and has reviewed all of the Company&#8217;s public filings on EDGAR since January 1, 2022. The Company agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">h) <u>Subsequent Equity Sales</u>.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">(i) From the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (A)&nbsp;issue, enter into any agreement to issue or announce the issuance or proposed issuance of any&nbsp;Common Stock or&nbsp;Common Stock Equivalents or (B)&nbsp;file any registration statement or any amendment or supplement to any existing registration statement (other than (x)&nbsp;the Prospectus Supplement or any resale registration statement referred to herein or (y) prospectus supplement to the Registration Statement to reflect the transactions contemplated hereby). Notwithstanding the foregoing, this Section&nbsp;(h)(i) shall not apply in respect of an Exempt Issuance. &#8220;<u>Exempt Issuance</u>&#8221; means the issuance of (a)&nbsp;shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b)&nbsp;shares of Common Stock issuable upon the exercise or exchange of or conversion of any securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this letter agreement, provided that such securities have not been amended since the date of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in this Section&nbsp;(h)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds. &#8220;<u>Person</u>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">(ii) From the date hereof until one hundred eighty (180) days after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of shares of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction. &#8220;Variable Rate Transaction&#8221; means a transaction in which the Company (i)&nbsp;issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of Common Stock either (A)&nbsp;at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities, or (B)&nbsp;with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security (other than in connection with a stock split or stock dividend or similar event) or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for shares of Common Stock or (ii)&nbsp;enters into, or effects a transaction under, any agreement, including, but not limited to, an equity line of credit or an &#8220;at-the-market offering&#8221;, whereby the Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement is subsequently canceled. The Holder shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.5in; text-align:justify;">(iii) Notwithstanding the foregoing, this Section (h) shall not apply in respect of an Exempt Issuance and, after the end of one hundred eighty (180) days after the Closing Date issuances pursuant to an at-the-market offering by the Company. </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">i) <u>Blue Sky Filings</u>. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the New Warrants and New Warrant Shares for, sale to the Holder at Closing under applicable securities or &#8220;Blue Sky&#8221; laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Holder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">j) <u>Stockholder Approval</u>. The Company shall use its reasonable best efforts to call a stockholder meeting within seventy (70) days of the Closing Date for the purpose of obtaining Stockholder Approval, with the recommendation of the Company&#8217;s Board of Directors that such proposals are approved, and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. If the Company does not obtain Stockholder Approval at the first meeting, the Company shall call a meeting every sixty (60) days thereafter to seek Stockholder Approval until the earlier of the date on which Stockholder Approval is obtained or the Common Warrants are no longer outstanding.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EXHIBIT A</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>NOTICE OF EXERCISE</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>TO: COSMOS HEALTH INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:0.5in">The undersigned hereby elects to purchase the number of Warrant Shares of the Company pursuant to the terms of the Existing Warrant set forth below and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Holder: <strong><u>________________________________________________________________ </u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px"><em>Signature of Authorized Signatory of Holder</em>: <u>_________________________________________</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Name of Authorized Signatory: <strong><u>____________________________________________________ </u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Title of Authorized Signatory: <u>____________________<strong>_________________________________ </strong></u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Number of Existing Warrants Exercised: <u>_________________________________________________</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Reduced Exercise Price: <strong><u>__________________________</u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Aggregate Warrant Exercise Price at the Reduced Exercise Price being exercised contemporaneously with signing this letter agreement: <u>_________________________________________________</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Existing Warrants Beneficial Ownership Blocker:&nbsp;&nbsp;&nbsp;&nbsp; &#9746; 4.99% or&nbsp;&nbsp; &#9744;&nbsp; 9.99%</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;New Series A Warrants: (up to 100% of total Existing Warrants being exercised): <strong><u>____________________________________</u></strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;New Series B Warrants: (up to 100% of total Existing Warrants being exercised): <strong><u>____________________________________</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">New Warrants Beneficial Ownership Blocker: &#9746; 4.99% or &#9744; 9.99%</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DTC Instructions: <u>_________________________________________________</u></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EXHIBIT B-1</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>FORM OF SERIES A WARRANT</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(See Attached)</strong></p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>EXHIBIT B-2</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>FORM OF SERIES B WARRANT</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(See Attached)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="margin:0px"> <p style="margin:0px"> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr></table></p> <p style="margin:0px"></p> <p style="margin: 0px"></p> <p style="margin:0px"> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cosm-20240926.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/26/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:cosm="http://cosm.com/20240926" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cosm.com/20240926">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://cosm.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20240926_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20240926_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20240926_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="cosm-20240926_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
 <import namespace="http://fasb.org/srt-roles/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd" />
 <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
 <import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
 <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
 <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
 <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>cosm-20240926_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/26/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address Country</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Security 12b Title</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cosm-20240926_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/26/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20240926.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>cosm-20240926_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/26/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20240926.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cosm-20240926_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 09/26/2024-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2024 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://cosm.com/role/Cover" xlink:href="cosm-20240926.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cosm.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46380542912464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">COSMOS HEALTH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001474167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 26,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-54436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0611758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">5 AGIOU GEORGIOU<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Pilea<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Thessaloniki<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">GR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">55438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">865-0026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">COSM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M='@//GL?)=-[*CG_5U/\!%!+ P04    "  *J3I9EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  JI.EFJQ"(6,P$
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M'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  *J3I9)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ "JDZ6660>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  *J3I9!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    (  JI.EDA;U'J[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  JI.EF97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ "JDZ6:H+%+0[!   \1   !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  JI.EF?H!OP
ML0(  .(,   -              "  7\,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ "JDZ69>*NQS     $P(   L              ( !6P\  %]R96QS
M+RYR96QS4$L! A0#%     @ "JDZ6:K$(A8S 0  (@(   \
M ( !1!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  JI.EDD'INBK0
M /@!   :              "  :01  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    (  JI.EEED'F2&0$  ,\#   3              "
M 8D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  -,3
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cosm_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cosm.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cosm-20240926.xsd</File>
    <File>cosm-20240926_cal.xml</File>
    <File>cosm-20240926_def.xml</File>
    <File>cosm-20240926_lab.xml</File>
    <File>cosm-20240926_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="cosm_8k.htm">cosm_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cosm_8k.htm": {
   "nsprefix": "cosm",
   "nsuri": "http://cosm.com/20240926",
   "dts": {
    "schema": {
     "local": [
      "cosm-20240926.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cosm-20240926_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cosm-20240926_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cosm-20240926_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cosm-20240926_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "cosm_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://cosm.com/role/Cover",
     "longName": "000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-09-26to2024-09-26",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-09-26to2024-09-26",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cosm_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 1",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Address Line 2",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address City Or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cosm.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001477932-24-005967-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-24-005967-xbrl.zip
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M33\/NI>^UH..U:]YEO?MNUY1EU[X5P1M_^=8M3_S$WVW_P-02P,$%     @
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MNU<>>_&[4FJ_=R%$GVY&K_;C]C=02P,$%     @ "JDZ64Z5B462 @  1 @
M !4   !C;W-M+3(P,C0P.3(V7V1E9BYX;6R]55MOVC 4?I^T_W"6/6R3YCC
M6@U46M'+0R4Z372;^E89YT"L.3:R':#_?K9#,E"I5"8Q'E"2\]W.B6.?7:Q+
M"4LT5F@U3#IIE@ JKG.AYL.DLH19+D0"UC&5,ZD5#I,GM,G%^=LW9^\(>;B<
MC.%:\ZI$Y>#*('.8PTJX D+ICEF'AI -^E?M,X!NVDNSK^WS2V8]2ZO(\<5.
M6[GV>J!GP(-RI&9]VCVEW:S[I07=ZYE;,8/ #"^$0^XJPR3D:,5<@0\.=4,#
M&'W@<%TP4[*%P9*IT!2,EBYMM:[TXLF(>>'@(_\$P09NR;>;'W!96:'06KC7
ML@I1[&>X53R%D90P"0P+$[1HEIAOY*10OP?A;^K[ S]H90=K*X9)X=QB0.EJ
MM4I7O52;N>\GZ]"'N_$]+WPN(E08.,>D8065?;Q.O]^GL=I GR'74R,;CQYM
MXK3*OIJ[EK -/J%UT4.M&-B8;*QY? ^O<( 7$>&.-# 2'I%.E_0ZZ=KFB1\<
M0#TZHR5.< 80+GY.;EM3KFV9<EW24*!7VJ]?'S)R"H.S81( )+R\K-\]#;+O
M=T#N:>'7L17E0OI!T"U+OX(:UWW0;8\7VFNF%OHZB=:%ES"\FB+)A?],PA>0
MP,9HNZM612A'/91N,'2OP+%3MU8DUR43!T9^SCYZWNA#2BRGX44?%':7>NRD
M3,K#\D7"L5,I[4:'!FLX_W$MXHQ5TOWS8FSHVXG]0Z%$V-7&_G8G-:X=JASS
M)G>0>\TNY(0+P*S^=8#\/2,)1"1\9W/T!\A,^\,H>-<;7Y-):KX31(9]5YOG
M\[--XQ9Y.M=+FJ.(IV.XB%M@/4$4C]%W-+7.,.X:)<FF**/^H\=LFMA,A^X9
M3SC7Z,[!=OX'4$L#!!0    (  JI.ED)@O/M#@8  '$Y   5    8V]S;2TR
M,#(T,#DR-E]L86(N>&ULS9M=;]LV%(;O!^P_G'D7VX#)BIVA6(PDA>NFA3$W
M#6)W*S8,A2S1-C&)-$@ZMO_]2'W%DD@I"5I*-XDC/H=\#\_K(\E6+E\?HA >
M$..8DJO>H'_6 T1\&F"RONKMN.-Q'^,><.&1P LI05>](^*]U]???W?Y@^-\
M?G,_@[?4WT6(")@PY D4P!Z+#:BA#QX7B#E.2O^9K#."8?^\?_9[?OR-QV44
M)7&,'!SD(V_E?$!7X*N9X]"S"W?XRAV>#7_+H3E=B;W'$'C,WV"!?+%C7@@!
MXGA-0 J')*$1C'_RX>W&8Y&W92CRB$H*Q@^BG\\UH=LCP^N-@)_]7T M U/G
M]F8!;W8<$\0YS&FX4U+XKS E?A_&80CW*H+#/>*(/: @G2[$Y+^1^K&4^8'<
M:,)'!XZO>ALAMB/7W>_W_?UYG[*US.=LX'[^,)O[&ZG+P41MN(]Z692:11<W
MN+BX<./1#*V0AR4+LS7.W4R.Q#D>\7BY&?7CS7U"&!@)]9>388XZY R&SOF@
M?^!!3^X&0+(?C(;H'JT@%CT2QZUT%,?1-E22XF,;AE9Z*2%CKHIW"5HKHZEE
M+M0R@U=JF1_3PS-OB<(>*/+3_=28U45AKC3(?:+4YTU^AQBFP0W)5OE*B9:G
M?:KXK[K\7'A,O&C+J_&6$UA0X84ODGX::5GT+7K9;C_&V=YEV?71RW;Y)/(;
MB!95P<_>6MV>ANK03+XJ"$0'@4B @DRBFJ"FX\;SQXT]GCF?F_J%64/5NRFK
MYLWEK/&,'/G]-7UP X3CTZ9ZX:@7<<KRCR\3*B\ QDLNF.>+;*8XB:N>9MPM
M"E+<F&6JY"FX(;&4<'TJ3W!;X82G+7'%:*1=-,V9:@:_A,L\/MD4N8169@%B
MB-,=\]&SZG&JU;1#J9XHE(2ZBD+$^33O7<<,_)-1_UZZC[-\\Q+?$('%\1ZM
ML5J=B%LO0IH\])B=@M=)S.JN8SI0_AI991<D*#RRH. 6O#"1%^SR*GDJ6]+A
M#W0T9E7A;+K!(+)HAQ+4&3_H=1D,D<(0TR!QJY;([N 6<D9-/L5A.P;02<KJ
M?CK6@7)KY)2KG-\B*\9J:<=RV4 M_2[TUAKQI7$[Q=6*RJI;&.Q >75ZRO7-
M&5!0"^W\)D)LC<GZ/:-[L9G0:.L1<U,WT#9;>ZW@8H/7HATP1K,Z0[//0B")
M@32HE9:??X:@/FJK:6XESNY)0"NR?#8H0!VP1YTNX_DA@4'2H/ 6.LF4^)1M
M*8L_$IP+*6)"=_+BY#BA@?F>H2'*9F=Y4@+%#E,;T@$K/5VEH>,40B&.A308
M5'0+/GN'0W2[BY:(&1,^16PZJ"JM:)?'\<YXHR+)8 3%00*V4/.%=Y@&LLWA
M%4Z^<F@P@)&WZ88&T45K&.#.^*1>G\$T,@B*4>U9:!P$<E=X^FN&"1H8D]6R
M-JU3([9H&PW8&<N8M1GLDI+Y;Q4"@TYX9?B,+(=M>V7X5*\,.^R5X0N\,FS/
M*Q/Y\B-;T#UIRO&4;,$G5:%:ESQB7?-(15F#0Q0/'QFHB!;]D5PT-R:786TX
MHRA1;XN$Z9PG"K*:#)' [7GACG+AA7_C;>V=L1YNP1=:N5IW%,BN>40GKL$I
M20C(&/LWNZIMC1GR#!XI#EOZ:ETC*?]F_62L Y77R*E\KQY76C+V:ZL>G OO
M-I28/\BH(G9J;)*6U;D\WH%:&R25ZQUC$'-MW(7.D;]CTG*#X7*!1:A[3U<1
M.S4W2<MJ7A[O0,T-DLHUSS"0',2@U9HOF*>>'YX?HR7595$:MU-MK:BLU(7!
M#M19IZ=<Y)2!!&KE37US\#=2$C(\'J7'[+ZY=1++;_!3I@/%KY%E?*-GK/W'
MH_Z2ZPM$)C2*=B3]N)-KLC)P=MQ0*S*S@Q;J@!_J=)4-D;)0A.TV!QIB'PO9
MFCYX C'L:3VN@2PU!J.\O"U4B Z8P"BJTA)R$#+2:OGO&%+F0[((\4->ZB%N
M]G&UTE[NU\%V[- L-[.%F>R /1K%E6TB ^ T I(0B&/:-,R4\QUBS[*-)J05
M\QBE&RQ4X;MG))/$1CLE@?6N.CTPDZ_4/P&FAW#RCW'7_P-02P,$%     @
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MKF2//A,  $>#   +    8V]S;5\X:RYH=&WM/6MWXD:RW^^OZ$LV&WP. B3
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M^\U=:,!%D34<:@.W'I2)C6*V0=NWY(R$XE%Z(2[E-7 4&T0%%__/0L_R"R]
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MIUG:*?$H)KJ^1-]( &</R*?-I$JG:4Q9! [^\'A:7GD"#/362>S/$%#D8Q/
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M4:R@SF;<DXN%>8H1].HX1]('H^3@L,07Z]$V+PTK<G%KDO_0N =5M8+?$7*
M2%;UL;_V1#K:@INX_TZ?-"FH'6.P%*;I<8WN=BL<;E%MU0.@>)7/%AD(76Y(
M=W&:PL2-A&3XFLE22K_.TR6P:]0MHC!<O<">PL$W ) B2>7]WX'1UPIC,YH2
M[6,2N92EQFN9F-O!3S(-L%\Z YJ)\\"BNXDH-A-<=F51L)AY40%8%96O*(+P
M(VSQWF!_"PWV3^X-]M_<8']-;7"].DCUZ('&H(1'P 7=</OI5<IAUUD^<:R"
M:K_#A-H&)Q8E:X3XMZG*'4@T$J#!3@+A$FV3>- /(2S5/]C8!UX:U R)$/G"
MB2*@V/0>)$- BXN,FO_$ZN\P&=WO$P3BF9,K+'4>?*)%J8/F(UA:NA/)8RW[
M)$FP2 -T@1W))HB*.:0O>S"_+75'RHU"69AD8R<JSXI2 E'8QFIC25E3Q/Y'
MVN=>0YV8V&!@;0&XEHX\&;5DT$ 7*"44D4D__V[:1G*W-0FX(_'_@D_?;VS!
MJ6@E*2ZL6*!55FR/7AMHMV@14-C5X#J( !I0.)NG7G+OLR'81X&E05IZNLU'
M_<I/N$4O.I=K;&!29$U]43$:8M90YC;=X2]>ZNHJZ3WVY7>6I?$C21:: [Q,
M"#+%:A*OMBH>%8'GG#<7<\_B!1NIJ?8WO5BY.NF$>_831?([A7-(WI+37#@/
MU# 1<$XNHD.57 J$SHPC.<-+*=&CK<8BGGEWPN&45A#"T3!ZE6$-HK=V8=@B
M; J1B.L-6/:&+)OZ;L"(0B$H3I]B?OV=8K@X6\U\/0-OET$)S0&BJ!411F$!
MEW*:"=1,0Y2JV\V=?2E>3@S>]$0:(?B-Y"6DHF_4< C&8[&XPB <DJJG@</*
M\@P2[[+ %]Q-R>@+R,<H.< 7;IC<UC!,$7=*W/ X5$O:MC&V[$/)R"(FW0W;
M4N:/Q?*!YW^&R4Z!\O;9ICK.C')TB&C#[(OD"7MN5<O*IOHO2SL;I.W"N!UG
M]1F.BI0<%0<9W/#3CRLE@17=  KI 63=F,Z!V17(/%^A)0^AG]//HK5Q&,BG
M%FS1-&(!_(R-"V&IG^/4C[B)8ZM5=&T/7BQY+J0@M%P)M30P,1*4R2K#,<F.
M83_]EA,A)BNW&(]";5S"T1V#-%8AZY%MMVU'8-[YID2_LY/,I57:")XA_$/7
M./<DLU&>$X18$.J)3FL_61-D7UV;8$QTXI,, ,3AB:$-/5&Y5F0SEFDD,(2I
M^$3?FB,_WYUB4O-I7WJE=5SW6-B=68\=47'&5CUC/8QL<D\(%]27$V#W\-0G
MQ&)2@J[(674V-W%F5U@34>)=,$X<#64UIT?DP)>(Q;IEF6@(G'+E&?9,&S7W
MT@:L'BTS)"+ PV8YO/2+@C-4T]*N'H:>Q1>%LRS;63?542B)30O-D5U"1?H.
MQG2^X1Y5@@Q]BJ2@CD$73>%2;:<E@4V8"0@Q6G_LGY1U7&)/<0FRA W191N[
M4;UZW\6N:!.I<Q!J#H[ZE6C(5UD!8FWI^PF^IO1P;XE::XEZ>F^)NGUEDP[_
M^<O1P='9-RF<]&W+N9M-OC\^.WIUJ([?J,-_'IZ\.CH]O O;]$I!R6;.CO=Z
MRF]_WUI87W0)F'A@\C[00A*0'KQ$68>S#V%6EW]+85-5T.,Y]+RVI-\UD0/&
MX>E5X D+6F*W/11[0"*8Z R[$Z*L03[XRE:X\./'NFY=8MU-!K)079Q+*U23
M(^')VRX.+O[DFG1_3<YU4P7$;ZZ>X]J*LK=@ZU^_JGA/-?%;L.^O6AG\MA_Z
M556^^W=M@'*=[=NMW\JS'Z[8;2M13V^L=/XMV/")GC8)G'%89ON::'[+<?G*
M8N*B%O;#X*9*C=\95/FB:N'=_W8*07=_W#6?^DI#WP)(\%AH>CS5Y ;<[Y8.
MWUY?.KR-79]92OSV7[X.C YN&8QNOQGUFU9<OP4HTU,]_?81SWL+V%H+V+-[
M"]CMM8 =;&S?61L8YH0?G_R*1K#3PY.CPU-DROLG)_O8E>V.[GETJK7:K^L8
MRVZ/OX4P<$_]UE*_[:U[\G>;R=_.G24%7?)W<$_^OMT6[^GB>KJX_:-1IA>3
M8KIZ^?\!4$L#!!0    (  JI.EE>J1J("4@  .:* 0 -    8V]S;5]E>#0Q
M+FAT;>U]"W/;1I;N7\'-3';)6Y B^1$GLL=5M$3'VI4EKR3'F3LUM042((D8
M!#@ *)GSZ^]Y]1, 2?D5R=%6[<0BP4;WZ>[S^,[KV:R>9\^?S9(H?OZL3NLL
M>3XNJOG_)A\>[>_"=\]^X ^?_9^=G:-BO)PG>1V,RR2JDSA85FD^#89'OPS.
M7T=5G90[.\^?_<!CC8IX%53U*DO^]MWE\+?+G<')\2^G!\'ORZI.)ZNGP<NS
MT\N#8']O40=U.D^J($^N@[*81_G3X/7@_)?CTYV3X4MXY,GW^H/SXU]>T2??
M/7^V4*/C0#L7Q_]OR*/QR#LO!Z^/3_Y^T#7V0;"W^/ TJ),/]4Z4I=/\H$RG
ML_HI#%S599%/GP]_>W7\XO@R>+2[_Q_YJ%H\#9[](%\]^V'Q//CL$U"4^>XY
MO^^SO<7\?YIWO%$M6OWW='A\^6IX'ER^.KX(+H:';\^/+_\>G)[A)T/UP?'P
M B9Q'KQ[=7SXRGL4_CW\;7A^>'PQ>'$R#%X-?AT&+X;#T^!\^,OQQ>7P?'@4
MO(-W^.,-3H_@AX>O!J>_#(/#L]>OCR\NCL].@^:;[2]?PN_^'EQ<#BZ'P3&^
MX^1X<'HX#-Z^@6\'ISB5UV\N\=&7YV>O90[G _KD[>G1L#'XX/ 21]W_^>'#
M,!C WZ^'\-A1T,/G_N,O/SUXL/?4?9P^W'_:#W$)\#^'AV?G1\>GOYS\/82]
M0-I= @%@T)>T=EC/Q=D)K77XYC)X\_;\XNW@]#*X/*/YPE.'E\= ,V>JM$"8
MR>6:29_[8PU^'1R?T":X5 CQ62#6((#A3R_@Q_@-3O/B[8O_@M?#[T-ZA3.'
M\^'_O#T^IUE<((E:YH![B ,3"6@?:*<';]Z<'!_23'BGK)^=#-Y=['I'"(?Q
M1H?]?DL#T,;* 1OR-.R?(L&!V&].@#<-:3*'9Z>G0UXB3R9X<78Z"%X>'PWE
MJM!\WYX2"<_H\)^< ?EH3!CC!9ROMW#,S6QV+7[0SA@F15[O5.F_DP.ZL?3G
M))JGV>K OZ_SJ)RF^0'<TH[KO\U]'@-S3DKK.E\,SVE3@G>#<]CD2S-1^6_0
M^.3R;(N'X(C!%07*7[P:G \OMOC%V<LM'L(K?7:ZQ8,7EV>'_]WX5-'-^_-+
M<U%-]:_^0I]K'YY=O#Z["%X-!R=PQ(]/#[_N$;4?N.G'=33*$O75J"AC4":J
M130&!>-@[ZDW2XL663*IGUZG<3V#K_:^_RX8)UFVB.(8?OBW[_9HZ%*-.TM0
MQA_L/Y9WQEWS>1>5902*SL4L*I/J('@4_O3D4;C_X$=>MUD]J$?QVI$V/-K0
M/^S?'E?5,@F.0-4Z""Z219W,1TD9/'@2!@_V'CS28\+_E/@_2$%_>^WAUGQE
M+^O^?_U-;A(M:"-HV]5]O/L8[SPIP,<@LU'E??!D=Q\_;%7$1(XQVVXR0.'C
M*-H]'HQ"D/EG0-PQZ-6SM%*ZRK.E.M//?E@^5[H*7)82WIO"-:]G41T&DZ(,
MKJ(,3EV9C)/T*HE!DRGG*<QNG 2'T2*MHRQ@73]XN<SCX*2.=P/X55I70515
ML)@*WYQ8+WY59'";G??"Q("'H6$!+U@NBCS G\"@<Q@%1JV6H]^3,1@&!7V1
MI7-X<9T6,#@\FWQ(RG%:)?0H?C\N\CCEKV=)F:1Y-,$)5DF-*ZIG81#5\/"*
MV"V. !/F1_#7%W4Q?C^C20:#Q:(L@ )TZ_R%'.?PDBC#E<!?P5!- Y]UEH?S
MXK<LRA3^%Y;Q^&!O+UCLSG>#WBEPU+\7Y?O@,*UY2OU *# !D@>]Q_U@E40P
MQ3R'O\LJ*E=!,=DTUZ@*XF22YF"7C9*LN.X'HV4=Y$6-/P2#C=;KK>@2* [4
M0M+YJPAQUK /U;A,1PF=#%S68EF.9Q$L>@)"(6@*'" U;$>Y*$H>-<W57V@O
MYK'0/(NN*[,FG#_\<9I<17'DS_&PF"]@[VP"XYG!Z6FV'%3$J'$0>'P.[R5"
MA<$B4@?ZKWN[>WO[P0+/!3[<\AKZ'0WDODSF*1,A2EL'-(KQ]I)=C'2F-8:!
M.[AU]P+XL_D2T'WA!YJX<&S&1)(B3P)'&&D:PA527\!ZL@PV/4C^M83C()=&
M'\\W.!CLBSD?*:P39H_[\Z WZN]NE P?S>DZ^1Q0X0AGP]<62;&K^ N(^5AX
MP;*"?^*QPV-<X#F^QA6I=?!EE_7/(K@[N/!Y$N4@_2MS_W'!R."(WT7PQ]ED
M D0\2>J6.V%_YYZ#F ZQ)8E_9$D,M(6C,W4.B6)-<E>1,49U 1>9+F-=[ ;'
M>8!J"NV";!DO6JTNR:KD&I_FZ9L-Y],U*3*XY0C \,^:ZT^!*XYISFH M>O[
M!Y\1PG"V_-'CKX]J[#Y&!=F9AGS6/@^]U8/)),U2E^\1^2J2%F^ ]Q:YB,8X
M!9%89RL2=KG^JYZ5Q7(ZHXL*W\P+VB[<D21.HQ)$:XCB":1W5M%/*_5GAHQZ
M)9_QK1XS#Y('@NL4CFXDTZ +7"W',R4FD1=4O+=XV.!'H",L-9<]7X(^_6CO
ML<5T8?>7)1PX(.E@7/NW_NZ@6!^]WR_2F+EA8[]#$7 KNN1\P9@)QTE-0I)W
MBX5T6=5**)A;.,XBV _6I()HL<A2M!QZ49_ID&HAHL43;CQ\EH-^4^$MA1G\
M:UG0OV!/@\LR0BL&U*WR?2*7?@0KT,*A,1ZN@?@(JCEP+OZU3"JZ[SWY(D]0
M\-0P!*AW-#@N5ZL?[AOQT^M9BB=NZXG#&2T3$/<UD^M%5A3(*J=!;Q15_L*.
MHA6K$3\?/-P+HD[E""7]P=Z#;O4)>#.(,4WGL\O#_WF!D\)__(:31?'13M!?
MWPW>=-*2KEM,VM5F GIO!4K0(1BC60;S&Z\_!Z*GM9"4-E5FWO(:N/HP))V)
M2A\ 9W3D%#2TWAGX"M6--VG^/CA;P#>RX;C*"&05F/^@-Q7E% 3)OUF/PV^F
M23Y>(5'&":\=-@;U_LDR'XMR/I&7X+<\IS[3>5X U9!HH*^80VRT,4]S"ZI"
M3S?$E_=B13\X02#M21D(QG"H*A&'40KLE]?!&A\,&76,3KJ0?:\CU%3C!&@1
MXPQAY\H(- VT(3)@],QFIT41XWN *PLK>",*6UGQV^;1[T6)QS+-60HDAE-8
MW)=VHUC650W;AZ3"7005'=@\G!:8#5!XP8B(: :B5LA2DX3-I.0#3+ABO9=O
MJE8%%U&J&9;\^(]A^%\6%#IH]1]]-!Z$3+RJX(O%:%::!2F09?UOY8L79^='
MP_.=%V>7EV>O#X)1%L&!VP>Y5159&OMR"XCYW?,MWV!\7O^Y@,NX,X(C\WZ'
M#+L#N!37T:KZS^<N++1^/']]'PTBM>(AG[+S7P2?_&-UCR(J8[RH1Z0Z%F75
M5#I)PJOG8O6<9W_^&?4V=#0G584:0[NJ'H,JP2(!U"_@\E&]+.&S,+@ ]3<B
M+9N_IC^47H/Z-AK)8#2/HOP]6DPD&$FS($!"5 V4(=&RG@%S_S<+YQ)L;=@@
MXK%9=(U\NDSF:%N.LP(T'04?+I\C2)/&28P3#_6GL^(ZN6(#DW5/X#QE.D%[
M+45EOS$UYNRH)HQ0*4WF:"07^,?-)A;$2Y(J0ET002M$QV;%/-'(C_INEF3H
MU$_SG05PL<;W>9'OP*X@D@?33.:+K%@EZJE ]&DFN]$I8A*6.$\P5U*E-[#:
M@C-<LKC&GRYFJPH( A0 JQ>V*RO& @)&I"S)%2'UA'\Q+8"F.6(Q\"NA"VPE
M*!,9&N@17S$2Z661IV-47>(*U:N\0JN_6H'R!<95+\W'V9)$,^[-=8HJE#Q4
M]?%M6Q\=4)J2$K9N18>H0&T+AP13 7=H#*<=*%\2KBGJYI_QAJ-VEE85;&4[
M5WR;IX2](%18V:H4JD'##Z"$Y5-6>WF4/RD)M8([!"8 6C!<A!8Q@S>E,B3T
MX$VYBQ?+494*A"'L\KI89K$"[FUTBS M'*8 U978CP.XNY"LOEHA 1R@!EOX
M?LC</!F!>08V%EPW9&45_Y(\9& -+/C):X$_-6]/"0$A)):,\+1RIC$N\BOT
M=Z!."<IY@3\45P+IF?0GGR3Z&ZYIJ <GW%&67G6L77PFH;/@/^%)U/=Q,*[;
MK[-U@>V'\2CN__SP$6%=T1R-L3C44&JYS.3"E\ETF8DH /$Z7V93@CEK#<#_
M":G.,&';;2>\$G00= Z@IF'<,^0@J4% 5;-T <9E">.&KL\&957N? (64@&"
MCW__>P%7*;B"FP&".^2;#,]D:31*,Y2%8V6Y\I-TE<V'1F S^) KE('0EQ%.
MNTH9G<);UC>7G>[B2@G^][#$/^&>$\B[_^A1<]?5-\[],'B B$GT.%5+9**"
M,[@0L<&<:;@YJ(JH;_+%9" <]$/@TX13(9)'C!;'@O^&2@54RA]>8%;]U/4-
MC&<RBH&OM\YQ%EVA(H:^R#HB73/C9RJ8":Y@48@O.)E,T"EG3_I/>"C</=S(
M@ W??7A7^>YGIE^+C[U)13IAD7+! ]WD=MCV%U+/@, =A!3UZS2JXNA?5HR%
M061S 5V![RJ^UY?KAK? 3+>ARY$'"2RMA?BJX4;!;6?O :&H_+CX%2N]Y6[\
MDXG0T)$7PH_9;:W>QB8J6C:("FL\$PP=A$'A<A8E?(Z*UXB\L/@T2H(B1SUU
M78C#;G#L+BPN$L;,;SP4JH2ODZ0F#ZD.SR!")BC&T@1(UGNR]ZQ:ZO-%:B,8
MHG)HX)ND_.YY/7OV _SS>9] !<L=B_,$2Y9=',J;Y!)IC/^CW+^XW6I&" H@
MQ_P LJWWXQZ-7=D1'!B5D23OZ52P84_.IS^"C'P%FHOH7K!Z1"V3*+Y"<G_>
MA4IF FQOCOP)/ORP@@L*PX+T0&]KG6:,(*!SASUV-U@Z&O)$L"3>#6X!Z[_'
MW3\&=V^+J'UP#\5_^U!\9Q!=NZY$/$)CQJT_3BL=,$DR5/!9UD<QIH^#,(Z2
M++I&[@'_^3,JI@I2Z@#Q*_V]K\=03"C*D3#@B"C;M0X<O1!4*6'XB&!A.U!G
MS="@E,S9F!'H*K9"0VGK1=7Y\^V7%:>QQNMB!XEX 21P+33@+2$,%O[WL4-P
MJ [&#J0%><K(Z,S0/T3.'_(D$*Z.VXU?_HGWCLG8OGV-$"8.GZAL)+1:'P6T
M*5I%7R(K&NF [9V_7PR#P1PV<1SE8;<)Y'SU2U:,UGYS0;X='<#$MUC[8@0;
M5XACP[@BX\2A#!AJ!2RE$2+[YSA![!0;3).\Y00AQ9,/@7HL#$Y.#D.Y?&5)
M(+P: 3&]VF.\H0IO!,T^(VX0QR7>87CLR4][*"MKL"J"%P58S5=1&:,O-X63
M]&#O0:B^#8.7)Y*<^_#!DP>/&;1P#>:UL_@3[BM&O-W9^,<8#LLJN"JR);#\
M:]*B46"#-0F[NR$R\D;1?'_2<,BO0-G[.,G[.,G[.,F&3/@HZ]I)$:9WI;0Q
M!R0*OGNN\SUV@Y:$FR^8"OQ%5_. 5J/RFV[Y4D@FMRPFZMN+P)-I)8GM!O87
MM9T:1D$0)%;@TB2Y=IE9^6#BB9A'<8+F%ASY@AUO\&_T]WKID*6<83\O4M(=
MW3Q'*[=QE*!^S)+2RR/$*<5)EA+*ZUY-9@#Q$JYO\@&N.K'N:$S,%&,T%N3[
M?7/TDO\-AOL\K665R0XJB\1^Y9]174?C&?J/^]J14M0BJ_3$TURI\W-,JH3W
M<NX8S,Q+_FK^V,W2>P=,348#"0<J3HG/]E*0RM<PV(.^+<V9^?12_!9EXI*R
MQN!YYQD$G<NT4IZ#"^1U& )ZD=1UEI!K_ V;NKVN%+ZXCS/@;+B^YXF();G2
M),W"M'#C*N!\S"=?28X:\439-O9=3:=@ .$ ;C*AEI^>GPC]3)A.'"N*6\ZO
MEFT9K=S(.@I.B*H94!4IOO_D*5!GEH <BLOH.F=MR8T$P]B[8)F+\9_0S^D/
MO=Q%68 &@E&%SNP,\<9]SI=%[>)F"]B%S^#!]SL@R^#>PU5I6:26-,HQ&((.
MHXB-]V&>Q/!/G,MT&2$U$U:C))QUM:#QS'?P%2A!42D:1U^%0+01V+P5YUJC
MQ67)TA6>Y:G*HI1K2LEG4;EJ.1H2?*H]G/ +%:*9X4U%JZ^1G.K=?N-ZD:&!
MJ6GF%K<[):_@IM,6:#=SPU&)HXR2Q.2&TPY.EH@8ICK<%U[1LJSM)DXQNN@[
MS21TX5JQ@A(W[*%W\V41+G;,UE/'04DK=?>8M+9&$KP!MDU!MO*TO,":+MR_
M94;Z9)IK@HJZ19HF1\GBJ'6!\(IA1]XM;J.WEV(K@1;P6[@XP)R$U]BJ6N?P
M,C?O!93%B'FT<$#</&;K"FX:$X_YI=E>=4A<3R1Z$LG9"5IV4<8866VXY>8W
MZ%$58R7C1Q.\S2.N6"I)/\H;EYS?CFLK)PM32GO[_<".?F?+89RDBUJ_.Z<1
M&BLGW)PJ,B1PZD=:6\Z5(6<G%$?C]WEQG27QE"5\-,53S9FOHY7HW%H7P8CV
MR@0OP$"@5L!/HL4L],2/UEO:#J)'8R]]?HL#BI=2O\'B#JS>3('J.2LYHA*Y
M(+&<MJJ.Q-AC^VC<!?E_(4WPL[MO[[VZGE?WX;U7]U,^OBT8YDO1.J.K(HT5
M'XN+Y8C!JS)A@"@8I^5X.:^8U1$<R9'KHK@X,@&X<)[4I#=BO0@5V*Z4CSMH
M6(Y<PU+GN[. L/1B%#OKJHG\=6_WY\<&>@HW%3WQ;:GF%+0==?>H.B:J'BKS
MP@$?NE5K3Z>V*I*PTATB)BG)3&R,6X::2BRP3K8)* "[+*UJ*;)#$HPV@S\F
MC2Q4[B\0UQ0 N.32$Q2VQ*,B^B9HL"-2\5=VJ*"CCLN:6-,(&:-KP _DDQ^9
MXQ9W Q%<TP(7/UJ):XET!3E(#8M.^2U26ZMV%/J1SM2(K;0,&+)3HW 43L23
M4W(528P7H1D80(];^H_>8.=%/^C]UO\G?MX;]"4FP2^I<LO"97Y\V%F+!]80
M_,T%X@\0T^"I($FX2H+K%4%M-)U3F9,Z ?O/0/VV=KP9!4A%C6TWB4 !YFF,
MP!XVB!$'V2AKR8YB-X9]U%=7B( #C#10:4&N ^2($T1[#S[7J^R!G1!3#&4@
M_\1$'6^.!#:>BUD!+U!'W -\* C_Q[V]WHB,_G,31G_Z^L()R#8U7R9)C.F'
M=KX7UM[JZWQ#:ZXA855, V%*G&NE-E+=^20E;*+WX2L=$=R<E?4N7<>EU2,E
MD\#@SW&Z@+5[?KQ.I]S)[IO=H"<;HS\V5=VT5:]8M:&)QJOXV%@T^Y3#K\]@
MO"0;>YLSTSB Y/FRL04%7 A@2;]F>2 UXDR$CJ USI,&(*:$XFW/LC^O_N:K
MA%-)N]C0C1A,PUYOIW>3<&L>_A0N\?$T]._L9U%__ABI\P*E#M*@I5(=ZY<"
MTQ,W>XHDOKN+_4TMME,'L0R5D:A?>* I]R)QO$&6KH6PV1AA+%+5***&&!25
M"&L\+(=?CW:-FJ6K=9$AI!\ _5+75(B:X/J-"P?>HQJ?$=5X=(]JW$I4XT:8
MQG$3W2SY]K/.QSDVS:LG(5KH%L#?=,*W;1Q"2:2'()%Z/VO'J9_[B9]AH#O%
MJ)A@VR9N.TK([<!S%J2UABD)J%ITCF1XDPN;T_0EU@=^';WGN.Y%47&Y3&U/
MT]A674OTYMU!<"$F<.%U@G&IZ;CRW<^W=T7[[>M))=Q$ @":LNXM"C470VFZ
M3<883]AVWHPOQF!/7 J'/,D2+^#@%%1K!32SM%;6!UZ*I8D']=1XJ6@=)^P_
MT9^/HHSND?HUW2><^E%"IQ,KO%YB%KT!&*5 * XG#^'H&$B 7FW.I#O$<'6P
MDG*I0*.M$"3CN\&A6SS;36!0P8<1<P,T>5@Q(-8AXU$4E%AM@[[!E."-&S&E
M!09WU)IP'<"05F,*J>X395V/2+B5[ RJ^2_Z;<\A)X0S-$T5+B6CNK]7140D
M=!&+L&*,1[E33';H<;MZN*V8ZQ1Y,+.KY9QB6!OA Q[ZU><(8U,29&25*8JM
M ]]<3JC!.1->('NHCQ='X:GGU%-YY)N;_OD,-6S7K5X63;C,*L/N4,;5$I4?
M5N*S38R$NP\RV?8X#VV *03&1-!PY%]W"(U)QND.*&I_,>,9VH_JV'8TJK]A
MG?$NWALEK.=SQ?5\PA*#GHZ][:@YKO9?<V._6OTN<V.?%FWD;$-:)=6-PL<I
MA5;JA*C"#'3R*'!@E !)G+I![,PNRB[%PD]?5P?8LFF:@1]AD);R&V1JA6O]
M;[JCJEH;']1%M)I;20.=YZ-GU9Z3>S#63N\&4^D[^8+7?V1(F7'6;][_1O;X
M)$JS2B<.2(P ;),.(7,D<,O^V@ZE-8S#+8#O'.2V5/-%M/*=%&O03%LL8I$\
MV"Q"(++T7\N4*[['T3R:2B@Q(<<5I9_E45:OF/,F$9S+O^Z'>WM[+:S76J;+
M64T6@$&WN@'-K1$O$%)_W=\CSYW-\Q#7PTT2Q]1?'S0?T6TH)O6LA5]NV(R^
MH47SM[3R-3^V(L.L:]#\E3(W#-@&[Y2MA&_![H\KC\R6AB$A'[:PBX(7R]7.
M<=X!VF%LY94"[EK-%'A<QQ1%6HF"=S*[4@81X^)62E5?"\.&ZH8/OQQ<7"([
MFI;1W*U@Z$1]X:NK1I"\5==L-QA((P7E<[0SH;LX0WLJ=*6>K\SS;-"%&&2/
M^H%4I.]@3:$Z8K[F _R*TC4]K-Z7 (V[$5'E116/YEZ4;5B:[[JEXZ_2_L+&
M^TW$5H_K0&I>99U'M_/+_H.M6K^T1EN'@7.&S#OL &YS-RT7LNN$L'M:N"S3
MG&$9/.0HW"4K?O9+PPTLW I&0^( \W[T\2O787;MWVKU8P-+4A%BK(E8 69?
M7\Z/5AMYX.<-..LPSN^!V2\-S#Z^!V8_.S#[97"J)E"%?$J'NK3 5,>>3\4*
MC&[&GW.,2T-#U?HH!J2)_1O9H;OD\S%AZ;X?1[JVC4E >-%#F^R;=MT\(O*I
M9Q/DC/E8B4/).'*U9HS]5X&W^/$R-ZB<)R(P/4 L1"]328DW^^5,4"=[4>1O
M17XQW#]"6\3996'(=PXFE?-WCFHKUSH\)UI;1\VWMH#N!A=U]4G:4P% -]M>
MW=IN?UN[*W=A.#M!@,X,!U^12NYJY'=OIZYHHW KDKQB@!3/LU@.\-=+V!U,
M,H(E7\)KLI6BUQ;0M]<)S%1-EYMG@O,\LS;]HB>DP[?L1O_[1R<:%5>):U_9
M[FL_<7#M$9.<;<M^% C1!C#M>HL(B8[*XKW'GWJ<7$)U9"3SF:@0C57*ML9S
M^RIHTO,'\*B8"3])R[F%_^K$C["C!Z$-B" H#X>GFD2F:GW0 FEWH&$^?(O%
M4-%F1(R"U4R*V5FH,!&#,T26S<=GUNULIR^SBZ0@)H)HBN B+4>&[6D.8\6T
M:TSIHVGV/O3;Z,BI1UZ?0RO@R-!YK O 5FKX?F?>86'YA)(/F'9?8<28;?+;
MP9QSS)1:9"M\(R+#ZX'SF8A8750SJIP<N':1FI*;,I?KH6^/2<.LV6,J^B_B
M?'R[D"(8":)WNTI0$J+^C!DM..=28'DG]0A6"&JHY*9%)GB,[Q$"(-O$]"%"
M0*X?GDU[O@XA#+K"?#?IJ'<"Y]N[<2<1.W=G15X@$7M.BI[WL(\TBT1)8KJK
MW5BCF577Q30!-T9_$R_V+')3QVKFZ0BL9JF ML1NG%ZT1OG26V$9G;O!2RJL
M%,$8B6;>,F.3L=<Q6ZF"'+5?(7CZK_N,/R+_+RC=3(FG)HB!>=/)G.HMVYXN
MK?AR:9[<,H2)2_&[MCV$-*<]G%.H^AM2B1AB*W*BVJ-#*:^=DS=\EN3GGT8.
MXV0(UDF%$TR8S7WW'I?H*,X%LE#=,K5_F-@&9K:MFJ(WH/1!)JBL1&@-QT Z
M&EO*O?764&G7!LJ=*S\T43(KJHI@*3LWEQ=!CDQM*6B>JG4MDKJ)K3_@A4D3
M3X-(G4:U< >P30P'Y2-EJ2K'^A8-<-#'&&""<V9OX!AA0,RO9^]X'O]  _Y.
M%4_(M0S79M(%YSE(X,1H4G+KU!UOW PN)M\2(6>Q*HM7^\7.I6_JY\OU^YHJ
M*6NDIT7PLF1M JN?"8'*X&)<I@N5G!),S".5?@0;.R],'0DJK-=X3E\ZX8O-
M2M"-0)Z!KJ*FAA,]AU2\AA+##-ARJ+O)&YJQ--6:+LN:V'+&@E?+-604$MUH
MY2ZYUYA&Y_QL/?7VO&1^4CTCZH3E$O=@0PQ=*)9DV*NSE\..2CX,$>8>^OLF
MH+\?[Z&_NP']73'T<@AW;XK&VV7T(5'=I+A8E E+TQ%/KH[7]/,J9HF5=[3D
M'-,K//U!.<W9!+"K%-;1![NCT9@ +ZK\0--JT3SL@*P6?VFHBFH(Z]4+U56Q
MUA7#"DT:1-=J3; J,;;V8"7AW?QM2?^MK*X)7*;7CREZ&OC]\P*_=1Z7*%#Q
M$U>Z]U-+*!F[L\QL(YF-<>FTSS]TT==KM)4U."O 9M-:0>@$*6A)A0%58R#!
M\Y)*$5'Q(E.+R"V*Y$("?BT+I)LH-IPP@=:FPI!X/!4BK%U;((.7<_C_">AK
MJ<!!H%[.1Z 78<\&?2J=PVB=P5KUKK]LZ.4D7[/,!YRH!)M6P*A6(-!W)Z;$
MN (K=$HZ7$<I# IFAF$GXJ3$%76&6G(]5VD/5"'_2RLD[SA+HI*;!^C.1TI?
M)7-#"OGI^GS]CBE;C0/7X^QW3YL4*%KUK8!5O2B*]U4S-I=P7C3>.7,)E2VK
M TDPPE]Q!"A75R$%:B4QF<*#0.6\HBX+RG/!Y[Y5H0SOJ-K>&>R=4+"W9\/I
M W]B@E6[XJ*1^*K34;Z.<'1YFB6<FB"]!6*L7,RG:Q\T[.N@IZ':(EBUYL0,
MWPIH(/-6*K21K/207:/,I,H76Y3B<F(3>W4Q38@+D+W92UNAR &PP0RAATKB
M1(W=S*W4,*V"S")BKU/0X%%[MT=V99P5J+GF529VM/D^L ?( LH3Y-#8K>U:
M>K.I@3O (3&BL+>;Y(]IY";VIVH,;54?0(5'6'#^_L->W)?@4IF='3<TJ.LR
M'7&(R1O.0;$!94R)EXFHI< -A\40QO!A+&6>"38QBSW3BS67P$F!IC)M?8;1
M[$G7=LR.!H_\(D(=I/.GV"IYD<N93:2/6DB@?9?<BF"KUQ,*PTATFPMFNRS
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MS=.+W>G-G>FY];982^>0X#&P30Z'4QFO)J_0/;':6:5:3UJOEP;O:@(AE1,
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M*!]O%,AT%*K.XRC7XS47TTQ^!R5\;#LOW6;7V*$>"R16# VAAI-4'6Y"7:G
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M>3A#LTPC6S*J_WM=6D2"'['<*D:)5+OE=)<>=VN"N]J_29P'N[U>SBD*MA6
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M?D1'4633YK*#7V[8C(&E1?NWM/(U/W9BRYQKT/Z5MJ0MH@?OE*V$;\&P2^N
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MFG/#\CYG)QT=GJ<;\*T9V[4DI<0>6*8C)-FV:RB<#&OB)MJ\D=NEKXZX;NF
MM@6SC]_J?J=.-FY'JIR;]QH$K2<3"<PSX?)L=3LA+-K\#-X5!TPK^+H=/C^Q
M^4ORUC3(+,)4)D)4MN+D/(AEQ.1]!*;4SY%WM(L;IURE^D"Y=K3+T!DZ<.'-
M+A?Y%O#,H$N\&7RSU!EEB3X)6'0.U,+"\-H9XZD6IJHB7;2P>VM*3KDM9.N"
M<6/[<A=<[3Z+?=0W8:H.L-PQWXV3C7:VC)SM"-CJP!ULBI&N4\2R07JUAZ\W
M'7L(RLB\^\+PH_86;00TPNMF=>0P4<2?6=>L;/TM6NP.I2)WQUIQ[<Q>;Y,+
MTVQ^T\#&4*^?D5%NZ+XB?<=J16=3GP&A F.0IO<*'4M%Q7NP'E)C-DP"BWD[
M. ;A4[?D\[3_N4.,_GC$Z,<[Q.AK0XS6%XA^ RK.&:HX1RZ,P2K=$7<@L>V8
MPDIQ/I+2JAU12Z]+.)R5%-&5@O(MA"5 53A"#(ZT0K'CZ7*BD3@/D)-AHQR,
M/0BA65:%:ZA[2,\VL7;A?+G&H\V$# -<8JM5XK<+5F+LE!)#$QAE@?[KZ31N
M63^Q4PL5;@SNPHQ<%3'%7'&6B?.Q,Q/)1W"*5 S\&@[N 0AB##H+P_GN3]>;
MC/+5AM1("%I?K==-\M:=EM8L,'FB1[UPD^^=X9SV9G>*K%4DNQ79%MW_<#75
M[J1XGMM'XW=63KUW?R6J:7A50L549M:GG_H0YD;U=,W;!M:W;N/OVC_:K)KR
M5 //Y>W75+^>!JJ<./1B6:3)G//Q+JR T-Z5&WI48I,=8Q!O3L7,5^S%UW^1
MC, X+50-..J,0Q4=(54+>LAPSUR1XX"C)TDO-:"FJWA0; "]BOBMFQ 3VT+7
M?HK?*D*(*P.66:T&_3-V9X/&<ASEBF1;GDTP\S66#MLLE'728\SA6BN-"1B=
MQW36P?M')7D0#45*-AQ'+WFV79&'HAY9&B:@;U02]M5%RM@F">D%NLN+W=;<
M-.E&UPJ<,M&5CE/D3W9TY&\[+M G.A4MU<+2KYG!DL(1#RVA(*TBF.TA\F?G
MY<P(WI:9:A[33@6,"C64#KR'3,K4>N=>Z-8+YDSIX?[?S!&5O=C"WZ1_0?$S
M'4-<E11YN  191)C)CR ]@X&?B/R3GV1>]76,T$/J69)D?W+1>)963:?];MN
M^$+ACB_SNM0>);M;[1- :EV_9F!<"%0P2>?0T/UV3D&ZY<ZSK^]S$A/9T7(^
MY\AT[?:3\VBO%15&]O7R\;)&5V?M^3TV&B#!]L2MS6$C8I>,",LT.VV$@0ZO
M=V\L/LW1Y/"P324$@:I+#G<_+=99'1[]3[@U'W=;HAWK\Y8&S+U5L)S0P'!5
M?BXEV*^4R%R1^H4Q6G22X.:4DXP.!?ZEPV:=>._-PS X^&GG!@PZLKA<JVZ-
M:/?]#^)88 77^'KZ$X%;2FI7G4YR)SKM#/S2C+W%TJR%Y9=M\RM[N4UU,7^B
M4F[!BIZ%K^_;L-%<0V;@Q3>6ZTL7#;;,&)5IV'@_/$ATE\(: V75D@L9PB6Z
M 4Z]K*XX<M;YE>1MDT^.?71)'H3R!?ZJH8GX.W0?\YI&\?YVA1FNVP&.8G#C
M&;>@CZWZMR[+J/-\K)W+Y]_P=HZ+L1G](E,MM_RZ()!D@;*KRH*X!!V+;-;9
MLVV1UQ3$5H?K>]Q<0K\R#(I!9DWMX)I-MZXS1PHF+P9BQ^)AFF*4]4Z3FV-@
MCQB:K<0N2]Z.J35->6? 7ZZ2?*GTCJ09ZK#(XU!-@945MAYUS_LHTFR=JHJQ
MP)(#<EG2$DSB[%I%E'$/4]6?EM5+R6Z(8*S?;O"QUA1ZJ=CH5]=6!O0B6K:[
MS[H-;S?!@$&Y_*#-7Z%6HD&A'8)"UZW=MS+0:M,L<X3PR*HCNS^HD!ZVY5OP
MV%[4M&/OPD19N*!JB$LBF6\Z+&6X@3OW]P<8M2^MQ6*]0M8)G?O=RX<$8$/5
MLG+@-/E95_Y6V>K:TS/X(';+JKM;695S]R1AW[EDU0KG)E@E55C;;ZQI&CL5
M[!#]]@Z4*6E'@ KYD<XG6):NCGZA*]BQ1660V>_ESO=E<9;M)D8AT==S)0T8
MQI$@A:;XT_KMDNQKI\U6:)S3\2YS%\JE-D_(QZ]:L98V&+],N'/9$9D?907L
MPKOG94%X;F?8EMG/#5<D=MK:?RSM+)]I5@LRCC KI'T6=B31SCQN8^S@7!)'
M3O7%[#HJ9;N20F\Q&=WZB+/I":.0+!<J0M;8?LA=##RP'WIJ+?<>)9L%G30!
M#6RZMJ$1>XL"8]G8?XWV Y#6H\?MG[J5/;2-S/C#@\'B5&=RT,>EI.U,0JEZ
M@Y4_L:ECTV6%4]4;T2\K U+C]/%RZ!TCPRA+A2S!U-9?:/JV[[4ZK,IFN)/9
M8>2NU3UQ=FW!P@IHZW.G&9>IFK^5D!QL6L^>5L@[;D:[D=:5O3!N[1-7\Z-Q
M=O4XIVP"H;9%[;'*5.6VIKGA)C*'TU_T*W5-,QSU>5Z6J+O/XNC5WIL]TV36
M?&ZL!3>MU6$_*WT 0U&Y6;!QP0^9O=&X.17=:("8MYU@8>GWNU.L+XSI8A6F
M$5><SE1Q 8O4$7MO]\[WX#T2#%WI6-I$MU#WY!OI"&/57"O5ED;;R6TO3;]O
MK5J!OG",!FYI0.G>!95>I&3UJQ+UW5RR"NQ,9["BAJTL##$Q(\(?M _.[]J'
MX.4O%]W['NTX&[O$W_^+:XK?_^$A%;CC1'@-&F*;@K(:.$? 3=)V#3A[ASY9
M XHIM9WEB"F-Q(7'%[H&-+>STQ?2+9GBA:T[1-1>#BR J/<[&-.71*85I.YL
ML,B7P=5%YE&4Q2Z9"![O<_HAA(.NE=->;\_+;':)9Y_:0J8<WD'SYH,]5K.L
M(.U+^$7?WMCJ.[0!'[4IY'?ITY.WV5/T^G%71_8W*K[$'5/W0![KXY5Z FO"
M[U-,<SDB!F(44P&.Z-Y_;DYPT\O/NSO""?Y+59AJR_41QL#6RFO)"O;[T'4I
M65HP4C8"QJ1@@(TIV(G1.&Y<OZG[#OP@K;42/$6-XKE&):EE;#?9=1GMT.;1
MP(J?++#>;AKT]W@7U$5$M6)1O<ZRCDS#"$\-9$W?(FOH.?"ALE A\# R1&BP
M$[ARJTTX3CVWJT.@%DD3>E>8ZW/ &+ [^:-RLN1(^ZU:[ 3G7 U\EXQ4WC"X
M,XU*RBM'G9*'<J(L]K*R36A*VVI:]Z'8"HHS:25K(=J^;F-<!)"]2QP]X))-
MPR^K7N5.=U"0)"M-@8QRY>G^^'Y9'4_531?-26Q]WXPJ4WH@ ^L4O@;2!82V
MDLF(C&WU5,IV+!)"M?C$#]S$0@U%;0QN8A7*@+OKLZ>V"W%:BYEN=T(81-1M
M1,Q@+',EGHGK?_EOXP=,$2+SFCX*[V )PX9]-!Q! -=I6>CV>B&8N(:D[IW:
M>/8]/6#=!..PN$K?0DR$>$ *5B""4IWX<^ 1C0.<*I#,Y1RD5K=ET>N-N0F.
M,)!=U1>DCZ.LN6>F[( M'>3[@PP OQ97;%THEB8D0\A:Y)F.%;\_:ZBB-E)Q
MIR[9Y&4[NTB=*$DMQ#:_OX-!WX3M@\FCJLJQ8D1 .0B3+8]##Q-S4XD!1D("
MR-:@>6L.D*+ZU.SA(V#%]<<:>]XD"(KH^Z+RSD@XC@J5(L8U:A;=C!)C/LG5
MB&794UU!2\^"PT3#,*\_(#3K+EGA2R<K_'27K'!;DA6FMSN'=D9AEH<65) ,
MBR&9*_93EP<:[3SH 6*:_20$8TTD+,3][.![N)88 FE[))5A-D2[<."&ZHSW
MMPQE\.J'2F4)*@O@!/\P^I,(:)VVNJ\[D,K&]VU3P*![&K<PE_QRP!VZ=(4X
MUGR^[NHN??UOJ5:-K5&#R_$C /B.O+M4A;H2=2H($8#C:6(A_/ZP*ZM/]9WD
MH-D(S'_1.)WA?/MRC*UP)V3UD;<+X: <V[WP5K2+7H;!#+9JA5/^04?E<.0,
MW0R/'OX%"/O/H)KEO3>)QA6VQ*-FFR[H@UJT+L9LO!+V5;?O[&1[_CT8(E9L
M:0Z[Y=P,#-L(RK?JK+3:2;PR@> =&6F$#0%1\6"@'6+B@/J2S1"4[WD?M3=,
M,*NCJ!"6X! O!'QM6ES!\=R52K&EIH."]+[OT']?L@2CO *RUP);)Z9&. 7K
M61?9&OM5=VFO3,$$MF3'' O T;:5$Z>XO@B.4RRATG]7D@>/**N H7!OD]S8
M;6ZMDM!%Z]07[W!:KHDC0:-MM)9@5V4.)K]4_LL*^R<<"] Q)2TJS^#U.@<!
M@T)8O"U-;XUD.DVRULS#%#F;'=>%9.JL*%WZL9L5^>Q*6A8"L1OG8<U*#/M*
MTPK16DJ;L2%9H$78*A.:Z9RI&59>;$<?8K-/A>^YMX^Z#!Q?^#G%PGB@@(-R
M2TX83L,'>]GV$E;)34"IU[#AL@WW4M6-H-=49>#JY5YM!@?H\ K<Q-Y5CYU+
M%W?< #H\J%<X;R.$V+YQ33K<=O>NG.K!>50WV&/-U.M-<^].LL/+L.HBJ$[U
M:Z6@.JDW.KP\EFP8ZS70/C #RQ+\*3Y*FD10/ BS>K#_DPT6;)$P:_Q1$'2Y
M*4D[,T^[\TBZHE"[ OF"LC%R58,HYL]&2"?BPJ0O.@UN36=;IW2L"#:NIHH_
MH%18FQ)H.H\U''GBY!TF4_T;A &SU '1;2ZR@#)!MP=SA6VK/II.9Z,']GS2
M;,WR=(54S8.H="T!;WP-I99JC<61X3B#4*6&,+OB;,NH4FTB4T-P6B.;08"4
M<0I( IAI(>&S8^"BH*4EA2J7-3JHD:6Z5#9(E%/&W=-*HT,.) 1F2E7AX7MJ
MVO?C[G]V])=FEV-P3$7!\<C2=N1B9H0J)HX[U,,A_0K3W1XWZ7L(3&2FK,XH
MOU2F,0N:CGZCW0_8D03I8WNV=&-JMT#+9#7S%R/\'6OE^4J?#M8QS_VF$=UM
M$8*0A]=)]5XU_E%#@KKAI\[F(L=N1[T%W2I8Z&K_%=X8QP[0/C2XHTNIW(Z:
M2"0!KJ'1HNMX<9PG+D9W>)%SAL/2)-GF=Z+4=8#C6 <TICJ@,5 @[IH4?Q-8
MZL'^'9CZM8&IZVL%/R#>=N%$>0A+^;K1I VU@O5ZDC%%LK5X<]CYBOB;-4V<
M<H!Y<ET;3=0TP@U:D1EB8IL<T9WH-YH9^SX]Q543HU>J:5I-@'5?6M';K<-Z
MFWHT%9EG$B;+(PQ8W3<$D3Y'W"">=3_,/XRUCBK=A]O>QT8+E@(+3J!I/C75
M3CU="DU.K)(_*[CCT(R3X/TV3C:ZQ+8N#E_IQUJXP=,WZ6\L,Z)ID*K7@/PI
M%#LH.7C);UQ,#8>#7L5.%69C$^L$3E&G]./B@&;?O2%G@F9:-C7*L;CO)2RK
M2\^4Y41.:W"T@>%6F,2'2O^S[NJ1S9152I)3Z=\UMW0V1SW6+7!8_Y<JO0)D
MN'_7'7J\$Q:#!]ZI>&!]OUQ34%O_]$@9KD.B;HSVVI/G@79(7>JEI-I ;)7P
M-1@N]?(K4))BS=W>5"2Q@UH924VHBDL!%M>^65RN:J DQ0*9O?;FY+?HB)9%
MCEB+,S;6'M!K"D(K"CB?>1[;F+2> DK;O=KDJ6  ],[]@1L<&62"%.URH'($
M:TKYL7>6KF/P(OXZ["^DE\,VCE%<LZGMHF'(X$>OZ=: L0ZRMUD@%*:%9TDR
M21V41]>P:/49%=YYF5QQB+)[%-E%= OEWIA=0G8IILFSLP.ZG4K&AC79SE1D
M70*J&,$P/(4XG726M,U3RJF6!0G6DZHQ1Z-3%O3S? WD$4<Q'6J1=]7"[ES&
M8TZ_LU$NB,5[!@R5S\YVW'^M.F#E>2+-U4I?(GC=:0@7OG+XHBYC;0GLE.SZ
M1"8?A#>JSN<$W.O8YHZP4 ^205>T?1W[2U'<R<)KM\Y&;4&T5!=7@Q=D**]M
M73B+)@1*CFUBB><8F:B&3IP'+<2PR0]FDI4MUL+*P2V\S%QL.\3<^[JV5QJ3
M]Q$!NKV,=NH3@4B2I'0$Q7KX-"6-@<>#Z.:NN=C*$1W*A\"L6L8QW^ \$JKL
M7=+_^\O!^X08 @MV3+&0H?B=R@S7.DXL4),Q^604%S0S+VT#_UYJLSRFP=&.
M0H-N'U6"/C"0C<%>"9.(\=WDRITT2W+JN=":5BENX4E,/7,*MI_[?]G8%:D+
M1AA29K>_WX[H<M&YK+6%;-'0/=\&E?$RVA3,R''.C!\1X."<GK%DG>4Z^,;K
MSZE[G?*7KJG84-B*5S]^C'&R]?L5&X_H6*$FX7DV,_V146[FRN@BZ%B<2W%4
M+%ZP6TYWZ8'*(3@Q<H'H.K%M4DO;A?;/EC#0P8,';811?L(V@;5NZ8IXJ8NV
M@EE8:+.LS)>JHSY,5V-2DK:K_IP$WSR^A9>&R^F=*4]U\M02R\HU;Y&ON?Z8
MT7I+JOXJX[!N9'WPE%Y+KC!;(R:4LG%'+0<],.7[Z$*ZKBK1V;HRJ%TR%<4*
M6*V)C,?IZ81X.$]7&5"/2W/ATY:S<M4C7%2>FR,6O%PCS$G5&'<4L(ZKK,R]
M%+'@CLK/UEU0N)2QUBN\T/R$6Y4;QD&J#OI15=K+%.Y*EG\KR/7!'7)]NY#K
MAX1<O\YJ/'#LCKW5F#5[A2<K&Q.<ECDFE['C3>=V,.X4^L31&H;/WH+U!0^<
M-U2"\(A^7YML?'@));7+YZX.SR_4;V+)WY&)87MDH=6/+W3&\\<P-CQ;G:PO
M2SY.YMJ.;B%'XK#.F&[>FO@?>Q(;3?/T,P&P7'>W$UR]YQ@UWF_<[M%432'F
MLE<B;GPG*(XIVR6F55".TJ5+.[78TVV]Y>H951+S0GI>?<E6N,VVE_7![-05
M^?X[%GK[[H%@6*7N- /KIX@;P?;>4L%G[9Q^$IU@#ZFFX2Z]N%F'27W9@7JE
MI>+@+(FA<-57V5:I*ZG#$%/39-*$]51F2E+8TR]=I[5J+]@M-#&3'K?1O9UT
M $9+[* =7?$3SB_N[T7O7!>0KFVI@[TP,,VN4!> "56LPM:(Q!@F J;UG/55
MZ.K8=6]G,I"VR7IHBH$29T9WFR]9)"F)_F=7 X'@8Z^;.#,(E[@!]EX 9>B]
M-9T"+QTT,$1NX65@#.A56<-Y!$-A"MSB"(W!Y42[9UYCG0VC#+MN6P]5F91
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MP&EWQ-I,K%MTX[Y"8_MKT:_O(*(0(GKT59^;&X$T3['0W[/_#U!+ 0(4 Q0
M   (  JI.EF]T^$GA@0  (,6   1              "  0    !C;W-M+3(P
M,C0P.3(V+GAS9%!+ 0(4 Q0    (  JI.EG1Z'I.V@$  (L#   5
M      "  ;4$  !C;W-M+3(P,C0P.3(V7V-A;"YX;6Q02P$"% ,4    "  *
MJ3I93I6)19("  !$"   %0              @ '"!@  8V]S;2TR,#(T,#DR
M-E]D968N>&UL4$L! A0#%     @ "JDZ60F"\^T.!@  <3D  !4
M     ( !APD  &-O<VTM,C R-# Y,C9?;&%B+GAM;%!+ 0(4 Q0    (  JI
M.EEGW,B6AP0  %PD   5              "  <@/  !C;W-M+3(P,C0P.3(V
M7W!R92YX;6Q02P$"% ,4    "  *J3I9<ZYDCSX3  !'@P  "P
M    @ &"%   8V]S;5\X:RYH=&U02P$"% ,4    "  *J3I9@K<N=%0I  #<
MV0  #@              @ 'I)P  8V]S;5]E>#$P,2YH=&U02P$"% ,4
M"  *J3I97JD:B E(  #FB@$ #0              @ %I40  8V]S;5]E>#0Q
M+FAT;5!+ 0(4 Q0    (  JI.ED$,R/6Y$<  .&& 0 -              "
H 9V9  !C;W-M7V5X-#(N:'1M4$L%!@     )  D -@(  *SA      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>cosm_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cosm-20240926.xsd" xlink:type="simple"/>
    <context id="From2024-09-26to2024-09-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001474167</identifier>
        </entity>
        <period>
            <startDate>2024-09-26</startDate>
            <endDate>2024-09-26</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2024-09-26to2024-09-26" id="ixv-400">0001474167</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2024-09-26to2024-09-26" id="ixv-401">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2024-09-26to2024-09-26" id="ixv-421">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2024-09-26to2024-09-26" id="ixv-422">2024-09-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2024-09-26to2024-09-26" id="ixv-423">COSMOS HEALTH INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-09-26to2024-09-26" id="ixv-424">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2024-09-26to2024-09-26" id="ixv-425">000-54436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-09-26to2024-09-26" id="ixv-426">27-0611758</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-09-26to2024-09-26" id="ixv-427">5 AGIOU GEORGIOU</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-09-26to2024-09-26" id="ixv-428">Pilea</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-09-26to2024-09-26" id="ixv-429">Thessaloniki</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2024-09-26to2024-09-26" id="ixv-430">GR</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2024-09-26to2024-09-26" id="ixv-431">55438</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-09-26to2024-09-26" id="ixv-432">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-09-26to2024-09-26" id="ixv-433">865-0026</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-09-26to2024-09-26" id="ixv-434">Common Stock, $.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-09-26to2024-09-26" id="ixv-435">COSM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-09-26to2024-09-26" id="ixv-436">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="From2024-09-26to2024-09-26" id="ixv-437">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2024-09-26to2024-09-26" id="ixv-438">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2024-09-26to2024-09-26" id="ixv-439">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2024-09-26to2024-09-26" id="ixv-440">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-09-26to2024-09-26" id="ixv-441">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
